



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: A61K 31/4523, 31/50	A1	(11) International Publication Number: WO 00/32193 (43) International Publication Date: 8 June 2000 (08.06.00)
(21) International Application Number: PCT/DK99/00671 (22) International Filing Date: 1 December 1999 (01.12.99) (30) Priority Data: PA 1998 01586 2 December 1998 (02.12.98) DK 60/111,445 8 December 1998 (08.12.98) US (71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): HANSEN, Anker, Jon [DK/DK]; Engbakkevej 20, DK-2920 Charlottenlund (DK). JØRGENSEN, Tine, Krogh [DK/DK]; Helgesvej 6, DK-3650 Ølstykke (DK). OLSEN, Uffe, Bang [DK/DK]; Horsbred 111, DK-2625 Vallensbæk (DK). (74) Common Representative: NOVO NORDISK A/S; Health Care Patents, Novo Allé, DK-2880 Bagsvaerd (DK).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS (57) Abstract The present invention relates to the use of N-substituted azaheterocyclic compounds or salts thereof, for the treatment of conditions related to angiogenesis.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS

5 FIELD OF INVENTION

The present invention relates to the use of N-substituted azaheterocyclic compounds of the general formulas Ia-I d for the treatment, prevention, alleviation or amelioration of conditions related to angiogenesis. Hence the compounds can be used in the treatment of patients
10 suffering from a variety of diseases like abnormal tissue growth, neoplasia, hyperplasia, cancer, diabetic retinopathy. The present invention also embraces pharmaceutical compositions comprising those compounds and methods of using the compounds and their pharmaceutical compositions.

15 BACKGROUND OF INVENTION

Tissue growth is critically dependent upon the formation of new capillaries, called angiogenesis or neovascularisation. The process may in pathological conditions be turned on by growth factors, e.g. vascular endothelial growth factor or cytokines, e.g. tumor necrosis factor
20 α . In e.g. cancer, angiogenesis is an important factor for the maintenance and growth of the tumor (Tanaka et al., Cancer Res., 58, 3362-3369, 1998). Angiogenesis is important for neoplastic conditions like cancer as well as ocular neovascularization like diabetic retinopathy (Favard et al., Diabetes and Metabolism 22, 268-273, 1996) . . Thus it has been shown that treatments directed against angiogenesis can e.g. inhibit tumor growth (Folkman, J., Breast
25 Cancer Res. and Treat., 36, 190-118, 1995, Tanaka et al., Cancer Res., 58, 3362-3369, 1998). The fact that angiogenesis is prominent in the female reproductive system suggests that treatments against angiogenesis are important for several conditions like bleeding disorders or in the context of birth control (Pepper, Arteriosclerosis, Thrombosis, and Vascular
Biology 17:605-619, 1997).

30 Thus one object of the invention is to provide compounds which can be used in the treatment of patients suffering from diseases in which neovascularisation or angiogenesis prevails or for the control of normal angiogenesis to obtain e.g. birth control.


WO 9518793 discloses N-substituted azaheterocyclic carboxylic acids and esters thereof, methods for their preparation, compositions containing them and their use in treatment of hyperalgesic and/or inflammatory conditions.

- 5 WO9631497, WO9631498, WO9631499, WO9631481, WO9711071, WO9815548, WO9815546, WO9815550, PCT/DK98/00273, PCT/DK98/00271, DK 0367/98, DK 0366/98, DK 1472/97 and DK 1523/98 discloses N-substituted azaheterocyclic compounds, methods for their preparation, compositions containing them and their use in treatment of hyperalgesic and/or inflammatory conditions as well as as well as their use for treatment of indications
 10 caused by or related to the secretion and circulation of insulin antagonising peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.

DESCRIPTION OF THE INVENTION

- 15 It has surprisingly been found that compounds of the general formulas Ia-Id below can be used in the treatment, prevention, alleviation or amelioration of an indication related to angiogenesis.

- Accordingly, the present invention relates to the use of a compound of the following groups
 20 of compounds having the general formula Ia



- 25 wherein R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, C_{1-6} -alkyl, C_{1-6} -alkoxy, hydroxy, NR^7R^8 , cyano, methylthio or $-SO_2NR^7R^8$ wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and

Y is $>\underline{\text{N}}\text{-CH}_2\text{-}$, $>\underline{\text{CH}}\text{-CH}_2\text{-}$ or $>\underline{\text{C}}=\text{CH-}$ wherein only the underscored atom participates in the ring system; or

Y is $-\underline{\text{CH}}_2\underline{\text{N}}(-)\text{CH}_2\text{-}$, $-\text{CH}_2\underline{\text{N}}(-)\underline{\text{C}}\text{H}_2\text{-}$, $-(\underline{\text{C}}=\text{O})\underline{\text{N}}(-)\text{CH}_2\text{-}$, $-\text{CH}_2\underline{\text{N}}(-)(\underline{\text{C}}=\text{O})\text{-}$, $-\underline{\text{CH}}_2\underline{\text{C}}\text{H}(-)\text{CH}_2\text{-}$, $-\text{CH}_2\underline{\text{C}}\text{H}(-)\underline{\text{C}}\text{H}_2\text{-}$, $-\underline{\text{C}}\text{H}_2\underline{\text{C}}(-)=\text{CH-}$, $-\text{CH}=\underline{\text{C}}(-)\underline{\text{C}}\text{H}_2\text{-}$, $-\underline{\text{O}}\underline{\text{C}}\text{H}(-)\text{CH}_2\text{-}$, $-\text{CH}_2\underline{\text{C}}\text{H}(-)\underline{\text{O}}\text{-}$, $-\underline{\text{S}}\underline{\text{C}}\text{H}(-)\text{CH}_2\text{-}$, $-\text{CH}_2\underline{\text{C}}\text{H}(-)\underline{\text{S}}\text{-}$, wherein only the underscored atom participates in the ring system; or

5 $\text{CH}_2\underline{\text{C}}\text{H}(-)\underline{\text{S}}\text{-}$, wherein only the underscored atom participates in the ring system; or

Y is $>\underline{\text{N}}\text{-}$, $>\underline{\text{CH}}\text{-}$, $>\underline{\text{N}}\text{-(C=O)-}$ or $>\underline{\text{C}}=\text{C(R}^8)\text{-}$, wherein only the underscored atom participates in the ring system and R^8 is hydrogen or $\text{C}_{1-6}\text{-alkyl}$; or

Y is $>\underline{\text{CH}}\text{-O-}$ or $>\underline{\text{CH}}\text{-S(O)}_y$, wherein y is 0, 1 or 2, or $-\text{N(R}^8)\text{-}$ wherein R^8 is hydrogen or $\text{C}_{1-6}\text{-alkyl}$, and wherein only the underscored atom participates in the ring system; and

10


X is completion of an optional bond, ortho-phenylene, $-\text{O-}$, $-\text{S-}$, $-\text{C(R}^7\text{R}^8)\text{-}$, $-\text{CH}_2\text{CH}_2\text{-}$, $-\text{CH}=\text{CH-CH}_2\text{-}$, $-\text{CH}_2\text{-CH}=\text{CH-}$, $-\text{CH}_2\text{-(C=O)-}$, $-(\text{C=O})\text{-CH}_2\text{-}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{-}$, $-\text{CH}=\text{CH-}$, $-\text{N(R}^8)\text{-(C=O)-}$, $-(\text{C=O})\text{-N(R}^8)\text{-}$, $-\text{O-CH}_2\text{-}$, $-\text{CH}_2\text{-O-}$, $-\text{OCH}_2\text{O-}$, $-\text{CH}_2\text{OCH}_2\text{-}$, $-\text{S-CH}_2\text{-}$, $-\text{CH}_2\text{-S-}$, $-(\text{CH}_2)\text{N(R}^8)\text{-}$, $-\text{N(R}^8)(\text{CH}_2)\text{-}$, $-\text{N(CH}_3\text{)SO}_2\text{-}$, $-\text{SO}_2\text{N(CH}_3)\text{-}$, $-\text{CH(R}^9)\text{CH}_2\text{-}$, $-\text{CH}_2\text{CH(R}^9)\text{-}$, $-(\text{C=O})\text{-}$, $-\text{N(R}^8)\text{-}$ or $-(\text{S=O})\text{-}$ wherein R^7 and R^8 independently are hydrogen or $\text{C}_{1-6}\text{-alkyl}$; and wherein R^9 is $\text{C}_{1-6}\text{-alkyl}$ or phenyl; and

15

p and q independently are 0 or 1; and

20 r is 0, 1, 2, 3 or 4; and


Z is selected from



wherein R^6 is OH or $\text{C}_{1-6}\text{-alkoxy}$; and

25 is optionally a single bond or a double bond; or

Z is selected from



wherein n is 1 or 2;

R^3 is $-(CH_2)_mOH$ or $-(CH_2)_sCOR^4$ wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein

5 R^4 is $-OH$, $-NH_2$, $-NHOH$ or C_{1-6} -alkoxy; and


R^5 is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{10} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{11} is hydrogen or C_{1-6} -alkyl; and

10 Z is optionally a single bond or a double bond; or

Z is selected from



wherein u is 0 or 1;

R^3 is $-(CH_2)_mOH$ or $-(CH_2)_sCOR^4$ wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein


5 R^4 is $-OH$, $-NH_2$, $-NHOH$ or C_{1-6} -alkoxy; and

R^5 is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{10a} is hydrogen or C_{1-6} -alkyl; and

A is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene; or

10 Z is selected from




wherein M_1 and M_2 independently are C or N; and

R^{35} is hydrogen, C_{1-6} -alkyl, phenyl or benzyl; and

R^{33} is hydrogen, halogen, trifluoromethyl, nitro or cyano; and


R^{34} is hydrogen, halogen, trifluoromethyl, nitro, cyano, $-(CH_2)_wCOR^{31}$, $-(CH_2)_wOH$ or $-(CH_2)_wSO_2R^{31}$ wherein R^{31} is hydroxy, C_{1-6} -alkoxy or NHR^{32} , wherein R^{32} is hydrogen or C_{1-6} -alkyl, and w is 0, 1 or 2; or

5 R^{34} is selected from



or

10 Z is




wherein b is 0, 1, 2, 3 or 4; and

B is $-CH=CR^{49}$ -, $-CR^{49}=CH$ -, $-C\equiv C$ -, $-(C=O)$ -, $-(C=CH_2)$ -, $-(CR^{49}R^{40})$ -, $-CH(OR^{41})$ -,

15 $CH(NHR^{41})$ -, phenylene, C_{3-7} -cycloalkylene or the completion of a bond, wherein R^{49} and R^{40} independently are hydrogen, C_{1-6} -unbranched alkyl, C_{3-6} -branched alkyl or C_{3-7} -cycloalkyl and wherein R^{41} is hydrogen or C_{1-6} -alkyl; and

U is




20

wherein R^{42} is hydrogen, $-(CH_2)_cOH$ or $-(CH_2)_dCOR^{47}$ wherein c is 0, 1, 2, 3, 4, 5 or 6 and d is 0 or 1 and wherein R^{47} is $-OH$, $-NHR^{44}$ or C_{1-6} -alkoxy wherein R^{44} is hydrogen or C_{1-6} -alkyl; and

R^{43} is cyano, $-NR^{45}R^{46}$, $-NR^{45}-V$ or $-(CHR^{48})_e-V$ wherein R^{45} and R^{46} independently are hydrogen or C_{1-6} -alkyl and wherein e is 0, 1, 2, 3, 4, 5 or 6 and wherein R^{48} is hydrogen, halogen, cyano, trifluoromethyl, hydroxy, C_{1-6} -alkyl, C_{1-6} -alkoxy, $-NR^{45}R^{46}$ or $-COOH$, and wherein V is C_{3-8} -cycloalkyl, aryl or heteroaryl, which rings may optionally be substituted with one or more

5 halogen, cyano, trifluoromethyl, hydroxy, methylthio, C_{1-6} -alkyl or C_{1-6} -alkoxy; or

U is selected from



wherein g is 0, 1 or 2; and

R^{11u} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{12u} is $-(CH_2)_hOH$ or $-(CH_2)_jCOR^{17u}$ wherein h is 0, 1, 2, 3, 4, 5 or 6 and j is 0 or 1 and where

5 R^{17u} is $-OH$, $-NHR^{20u}$ or C_{1-6} -alkoxy wherein R^{20u} is hydrogen or C_{1-6} -alkyl; and


R^{13u} is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{14u} is hydrogen or C_{1-6} -alkyl; and

C is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene; and

... is optionally a single bond or a double bond; and

10 R^{18u} is selected from




wherein M_1 and M_2 independently are C or N; and

R^{19u} is hydrogen, C_{1-6} -alkyl, phenyl or benzyl; and

R^{15u} is hydrogen, halogen, trifluoromethyl, nitro or cyano; and

15 R^{16u} is hydrogen, halogen, trifluoromethyl, nitro, cyano, $-(CH_2)_kCOR^{17u}$, $-(CH_2)_kOH$ or $-(CH_2)_kSO_2R^{17u}$ wherein k is 0, 1 or 2; or


R^{16u} is selected from



20 or


Z is selected from

9



wherein R^{53} is $-(CH_2)_{pp}COOH$ wherein pp is 2, 3, 4, 5 or 6; or

5 Z is




wherein tt and t independently are 0, 1 or 2; and

R^{63} is H, C_{1-6} -alkyl or optionally substituted benzyl;

- 10 R^{64} and R^{65} independently are H, C_{1-6} -alkyl, C_{3-7} -cycloalkyl, phenyl, thienyl, benzyl, or R^{64} and R^{65} together with the C-atom they are attached to form a 3 - 8 membered carbocyclic ring; and
- R^{66} is H or C_{1-6} -alkyl; or

15 Z is selected from




wherein D is $-CH_2-$, $-O-$, $-S-$ or $-N(R^7)-$ wherein R^7 is hydrogen or C_{1-6} -alkyl; and

R^{3m} is $-(CH_2)_{mm}OH$ or $-(CH_2)_{mp}COR^4$ wherein mm and mp are 1, 2, 3 or 4 and R^4 is OH, NH_2 ,

20 NHOH or C_{1-6} -alkoxy; or

having the general formula Ib



5


wherein R^{1b} and R^{2b} independently are hydrogen, halogen, trifluoromethyl, hydroxy,

C_{1-6} -alkyl or C_{1-6} -alkoxy; and


R^{3b} is hydrogen or C_{1-3} -alkyl; and

A_b is C_{1-3} -alkylene; and

- 10 Y_b is $>\underline{C}H-CH_2-$, $>\underline{C}=CH-$, $>\underline{C}H-O-$, $>\underline{C}=N-$, $>\underline{N}-CH_2-$ wherein only the underscored atom participates in the ring system; and
- Z_b is selected from



11



wherein nb is 1 or 2; and

R^{11b} is hydrogen or C_{1-6} -alkyl; and

- 5 R^{12b} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{13b} is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and


R^{14b} is $-(CH_2)_{mb}OH$ or $-(CH_2)_{mb}COR^{15b}$ wherein mb is 0, 1, 2, 3, 4, 5 or 6 and tb is 0 or 1 and wherein R^{15b} is $-OH$, NH_2 , $-NHOH$ or C_{1-6} -alkoxy; and

- 10 R^{16b} is C_{1-6} -alkyl or $-B_b-COR^{15b}$, wherein B_b is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene and R^{15b} is the same as above; and

\sim is optionally a single bond or a double bond; or

having the general formula 1c

12



(1c)

wherein R^{1c} and R^{2c} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy;


- 5 X_c is ortho-phenylene, -O-, -S-, $-C(R^{6c}R^{7c})-$, $-CH_2CH_2-$, $-CH=CH-CH_2-$, $-CH_2-CH=CH-$, $-CH_2-(C=O)-$, $-(C=O)-CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-N(R^{8c})-(C=O)-$, $-(C=O)-N(R^{8c})-$, $-O-CH_2-$, $-CH_2-O-$, $-OCH_2O-$, $-S-CH_2-$, $-CH_2-S-$, $-(CH_2)N(R^{8c})-$, $-N(R^{8c})(CH_2)-$, $-N(CH_3)SO_2-$, $-SO_2N(CH_3)-$, $-CH(R^{10c})CH_2-$, $-CH_2CH(R^{10c})-$, $-(C=O)-$, $-N(R^{8c})-$ or $-(S=O)-$ wherein R^{6c} , R^{7c} , R^{8c} and R^{9c} independently are hydrogen or C_{1-6} -alkyl, and wherein R^{10c} is C_{1-6} -alkyl or phenyl;

- 10 Y_c is C or N;

_____ is optionally a single bond or a double bond, and _____ is a single bond when Y_c is N;

mc is 1, 2, 3, 4, 5 or 6; and

Z_c is $-COOR^{3c}$ or




15

wherein R^{3c} is H or C_{1-6} -alkyl; or

having the general formula 1d

20


13



(Id)

wherein R^{1d} and R^{2d} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

- 5 X_d is -O-, -S- or -S(=O)-; and
 rd is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and
 Z_d is selected from



- wherein R^{3d} is $-(CH_2)_{md}OH$ or $-(CH_2)_{pd}COR^{4d}$ wherein md and pd independently are 0, 1, 2, 3 or 4 and R^{4d} is OH, NH_2 , $NHOH$ or C_{1-6} -alkoxy; or
- 10 a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention, alleviation or amelioration of a condition related to angiogenesis.
- 15 The compounds according to the invention may exist as geometric and optical isomers and all isomers, as separated, pure or partially purified stereoisomers or racemic mixtures thereof are included in the scope of the invention. Isomers may be separated by means of standard methods such as chromatographic techniques or fractional crystallisation of suitable salts.
- 20 Preferably, the compounds according to the invention exist as the individual geometric or optical isomers.

The compounds according to the invention may optionally exist as pharmaceutically acceptable acid addition salts, metal salts or, optionally alkylated, ammonium salts.

Examples of such salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate or similar pharmaceutically acceptable inorganic or organic acid addition salts.

- 5 Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) which are known to the skilled artisan.

- 10 Also included are the hydrates of the above mentioned acid addition salts which the present compounds are able to form.

The acid addition salts may be obtained as the direct products of compound synthesis. In the alternative, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or by precipitation or crystallisation.

15

The compounds according to the invention may be administered in a pharmaceutically acceptable acid addition salt form or where possible as a metal or a lower alkylammonium salt. Such salt forms exhibit approximately the same order of activity as the free base forms.

- 20 In the above structural formulas and throughout the present specification, the following terms have the indicated meaning:

- The terms "C₁₋₆-alkyl" and "C₁₋₈-alkyl" as used herein, alone or in combination, refers to a straight or branched, saturated hydrocarbon chain having 1 to 6 and 1 to 8 carbon atoms respectively. Examples of such groups include, but are not limited to, methyl, ethyl, n-propyl, 25 iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, iso-pentyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, iso-hexyl, 4-methylpentyl, neopentyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1,2,2-trimethylpropyl and the like.

- 30 The term "halogen" means fluorine, chlorine, bromine or iodine.

The term "C₁₋₆-alkoxy" as used herein, alone or in combination is intended to include those C₁₋₆-alkyl groups of the designated length in either a linear or branched or cyclic configuration linked through an ether oxygen having its free valence bond from the ether oxygen. Examples of

linear alkoxy groups are methoxy, ethoxy, propoxy, butoxy, pentoxy and hexoxy. Examples of branched alkoxy are isoprpxoxy, sec-butoxy, tert-butoxy, isopentoxy and isohexoxy. Example of cyclic alkoxy are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy.

- 5 The terms " C_{3-7} -cycloalkyl" and " C_{3-8} -cycloalkyl" as used herein, represents a carbocyclic group having from 3 to 7 carbon atoms and having from 3 to 8 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl and the like.

- 10 The term " C_{3-7} -cycloalkylene" as used herein represents a bisubstituted carbocyclic group having from 3 to 7 carbon atoms e.g. cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene and cycloheptylene and the like.

- 15 The term "aryl" as used herein is intended to include carbocyclic aromatic ring systems such as phenyl, naphthyl (1-naphthyl or 2-naphthyl), anthracenyl (1-anthracenyl, 2-anthracenyl, 3-anthracenyl), phenanthrenyl, fluorenyl, indenyl and the like.

- 20 The term "heteroaryl" as used herein is intended to include heterocyclic aromatic ring systems containing one or more heteroatoms selected from nitrogen, oxygen and sulfur, such as furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, triazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, thiadiazinyl, indolyl, isoindolyl, benzofuryl, benzothienyl, indazolyl, benzimidazolyl, benzthiazolyl, purinyl, quinoxoliny, quinolinyl, isoquinolinyl, quinoxaliny, naphthyridinyl, pteridinyl, carbazolyl, acridinyl and the like. Heteroaryl is also intended to include the partially or fully hydrogenated derivatives of the heterocyclic systems enumerated above. Non-limiting examples of such partially or fully hydrogenated derivatives are pyrrolinyl, pyrazolinyl, indolinyl, pyrrolidinyl, piperidinyl, piperazinyl, azepinyl, diazepinyl, morpholinyl, thiomorpholinyl, oxazolidinyl, oxazolinyl, oxazepinyl, aziridinyl and tetrahydrofuranly.

- 30 The term "3- to 8-membered carbocyclic ring" as used herein refers to a monocyclic unsaturated or saturated ring containing from 3 to 8 carbon atoms. The term includes, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl and the like.

In a preferred embodiment of the invention in formula Ia

R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, C_{1-6} -alkyl or C_{1-6} -alkoxy; and


Y is $>\underline{N}-CH_2-$, $>\underline{CH}-CH_2-$ or $>\underline{C}=CH-$ wherein only the underscored atom participates in the ring system; and

- 5 X is $-O-$, $-S-$, $-C(R^7R^8)-$, $-CH_2CH_2-$, $-CH=CH-CH_2-$, $-CH_2-CH=CH-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-N(R^8)-(C=O)-$, $-O-CH_2-$, $-(C=O)-$ or $-(S=O)-$ wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and

p and q are 0, and

r is 1, 2 or 3; and

- 10 Z is selected from



wherein R^6 is OH or C_{1-6} -alkoxy; and

--- is optionally a single bond or a double bond; or
a pharmaceutically acceptable salt thereof.

15

Preferred compounds of the present invention include

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

20

(S)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid;

25

(R)-1-(3-(Fluoren-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(Thioxanthen-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

5

(R)-1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-butyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)ethyl)-3-piperidinecarboxylic acid;

10 (R)-1-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10H-Phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

15 (R)-1-(3-(10H-Phenoxazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(S)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-pyrrolidinacetic acid;

20

(R)-1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(2-Trifluoromethyl-10H-phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

25

(R)-1-(3-(5-Oxo-10H-phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11H-10-Oxa-5-aza-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

30

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid;

(R)-1-(3-(6,7-Dihydro-5H-dibenzo[b,g]azocin-12-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

5 (R)-1-(3-Methoxy-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10-Methyl-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

10

(R)-1-(3-(9(H)-Oxo-10H-acridin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-ethyl)-3-piperidinecarboxylic acid hydrochloride;

15

(R)-1-(2-(6,11-Dihydrodibenz[b,e]oxepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Chloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

20

(R)-1-(3-(2-Bromo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

25

(R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

30

(Z)-(R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;


(E)-(R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-
5 piperidinecarboxylic acid hydrochloride.

In another preferred embodiment of the invention in formula Ia

R¹, R^{1a}, R² and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and

- 10 Y is -CH₂N(-)CH₂-, -CH₂N(-)CH₂-, -(C=O)N(-)CH₂-, -CH₂N(-)(C=O)-, -CH₂CH(-)CH₂-, -CH₂CH(-)CH₂-, -CH₂C(-)=CH-, -CH=C(-)CH₂-, -OCH(-)CH₂-, -CH₂CH(-)O-, -SCH(-)CH₂-, -CH₂CH(-)S-, wherein only the underscored atom participates in the ring system; and
X is -O-, -S-, -C(R⁷R⁸)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R⁸)-(C=O)-, -(C=O)-N(R⁸)-, -O-CH₂-, -CH₂-O-, -S-CH₂-, -CH₂-S-, -
15 N(R⁸)-, -(C=O)- or -(S=O)- wherein R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl; and
p and q independently are 0 or 1; and
r is 1, 2 or 3; and
Z is selected from



- 20 wherein R⁶ is OH or C₁₋₆-alkoxy; and
... is optionally a single bond or a double bond; or
a pharmaceutically acceptable salt thereof.

Further preferred compounds of the invention include:

- 25 (R)-1-(3-(6,11-Dioxo-6,11-dihydro-5H-dibenz[b,e]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(6,11-Dihydro-5H-dibenz[b,e]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(5,11-Dihydro-10H-dibenzo[b,e][1,4]diazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11H-Dibenzo[b,f][1,4]thiazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

5

(R)-1-(3-(11H-Dibenz[b,f][1,4]oxazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11H-Dibenz[b,f][1,4]oxathiepin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

10 (R)-1-(3-(11H-Dibenzo[b,e][1,4]dithiepin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11H-Dibenz[b,e][1,4]oxathiepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

15 (R)-1-(3-(11,12-Dihydro-10H-dibenz[b,g][1,5]oxazocin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11,12-Dihydro-10H-dibenzo[b,g][1,5]thiazocin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

20 1-(3-(11,12-Dihydro-6H-dibenz[b,f]azocin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(11,12-Dihydro-5H-dibenzo[a,e]cycloocten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

25 1-(3-(6-Oxo-11,12-dihydro-5H-dibenz[b,f]azocin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(7,12-Dihydro-6H-dibenzo[a,d]cycloocten-6-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

30 1-(3-(5-Methyl-5,11-dihydro-dibenz[b,f]azepin-10-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(6-Oxo-5,11-dihydro-5H-dibenz[b,e]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11-Oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

5 (R)-1-(3-(6-Oxo-11,12-dihydro-5H-dibenz[b,f]azocin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-dibenz[b,f][1,4]oxazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

10 (R)-1-(3-(5,6,11,12-Tetrahydro-dibenz[b,f]azocin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11-Oxo-6,11-dihydro-5H-dibenz[b,e]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

15 (R)-1-(3-(5-Methyl-dibenz[b,f]azepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(6,7-Dihydro-5H-dibenz[b,g][1,5]oxazocin-6-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11,12-Dihydro-dibenz[a,e]cycloocten-5-yl)-1-propyl)-3-piperidinecarboxylic acid.

20 In another preferred embodiment of the invention in formula Ia


R¹, R^{1a}, R² and R^{2a} independently are hydrogen, halogen, trifluoromethyl, NR⁷R⁸, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy wherein R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl; and

Y is >N-CH₂-, >CH-CH₂- or >C=CH- wherein only the underscored atom participates in the ring system; and

25 X is -O-, -S-, -C(R⁷R⁸)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R⁸)-(C=O)-, -(C=O)-N(R⁸)-, -O-CH₂-, -CH₂-O-, -S-CH₂-, -CH₂-S-, -N(R⁸)-, -(C=O)- or -(S=O)- wherein R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl; and p and q are 0; and

r is 1, 2 or 3; and

30 Z is selected from



wherein n is 1 or 2; and

R^3 is $-(CH_2)_mOH$ or $-(CH_2)_sCOR^4$ wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein

5 R^4 is $-OH$, $-NH_2$, $-NHOH$ or C_{1-6} -alkoxy; and

R^5 is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{10} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{11} is hydrogen or C_{1-6} -alkyl; and

10 --- is optionally a single bond or a double bond; or
a pharmaceutically acceptable salt thereof.

Further preferred compounds of the invention include:

15 1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidine-carboxamide;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-piperidinecarboxylic acid;

(1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidinyl)methanol;

4-(4-Chlorophenyl)-1-(3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinol;

5 4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-piperazinecarboxylic acid;

(2S,4R)-1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-hydroxy-2-pyrrolidinecarboxylic acid;

10 4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-morpholinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-aziridinecarboxylic acid;

15 2-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-1,2,3,4-tetrahydro-4-isoquinolinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-methyl-[1,4]-diazepane-6-carboxylic acid;

20 2-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid hydroxamide;

25

(4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)piperazin-1-yl)acetic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

30 4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-piperazinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidineacetic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxamide;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-pyrrolidinecarboxylic acid;

(S)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-pyrrolidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-piperidinecarboxylic acid;

1-(3-(10H-Phenoxazin-10-yl)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(3-Chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidineacetic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-methyl-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-quinuclidiniumcarboxylate;

1-(3-(2,8-Dibromo-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(3,7-Dichloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

5 1-(3-(3,7-Dimethyl-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(3-Dimethylamino-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

10 (R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-piperidinecarboxylic acid;

(S)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-piperidinecarboxylic acid;

15

1-(2-(6,11-Dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(6,11-Dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-4-piperidinecarboxylic acid;

20 1-(2-(2-Chloro-6,11-dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(2-Chloro-6,11-dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-4-piperidinecarboxylic acid;

25

(R)-1-(2-(6,11-Dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid;

1-(3-(2-Bromo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-pyrrolidineacetic acid;

30

1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-pyrrolidineacetic acid;

1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(2-Fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

5 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-2-piperidineacetic acid;

1-(3-(Phenothiazin-10-yl)-1-propyl)-4-piperidinecarboxylic acid;

10 (R)-1-(2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-ethyl)-2-piperidinecarboxylic acid;

1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-ethyl)-4-piperidinecarboxylic acid;

15 1-(2-(6,11-Dihydrodibenzo[b,e]oxepin-11-ylidene)-1-ethyl)-4-piperidinecarboxylic acid.

In another preferred embodiment of the invention in formula Ia

R¹, R^{1a}, R² and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and


20 Y is $\text{>}\underline{\text{N}}\text{-CH}_2\text{-}$, $\text{>}\underline{\text{CH}}\text{-CH}_2\text{-}$ or $\text{>}\underline{\text{C}}\text{=CH-}$ wherein only the underscored atom participates in the ring system; and

X is ortho-phenylene, $\text{-CH}_2\text{-(C=O)-}$, $\text{-(C=O)-CH}_2\text{-}$, $\text{-S-CH}_2\text{-}$, $\text{-CH}_2\text{-S-}$, $\text{-(CH}_2\text{)N(R}^8\text{)-}$, $\text{-N(R}^8\text{)(CH}_2\text{)-}$, $\text{-N(CH}_3\text{)SO}_2\text{-}$, $\text{-SO}_2\text{N(CH}_3\text{)-}$, $\text{-CH(R}^9\text{)CH}_2\text{-}$ or $\text{-CH}_2\text{CH(R}^9\text{)-}$ wherein R⁸ is hydrogen or C₁₋₆-alkyl and R⁹ is C₁₋₆-alkyl or phenyl; and

25 p and q are 0; and

r is 1, 2 or 3; and

Z is selected from



30 wherein R⁶ is OH or C₁₋₆-alkoxy; and

..... is optionally a single bond or a double bond; or

a pharmaceutically acceptable salt thereof.

Further preferred compounds of the invention include:

5 1-(3-(9H-Tribenz[b,d,f]azepin-9-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(Tribenzo[a,c,e]cyclohepten-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(5-Methyl-5,6-dihydrodibenz[b,e]azepin-11-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

10

1-(3-(6-Methyl-6H-dibenzo[c,f][1,2]thiazepin-5,5-dioxide-11-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(10-Methyl-10,11-dihydro-5H-dibenzo[b,e]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

15

1-(3-(10-Phenyl-10,11-dihydro-5H-dibenzo[b,e]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

20 1-(3-(6,11-Dihydro-11H-dibenzo[b,e][1,4]thiazepin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(10-Methyl-10,11-dihydro-dibenzo[b,e][1,4]diazepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

25

(R)-1-(3-(10-Oxo-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(6-Methyl-6,11-dihydro-dibenzo[c,f][1,2,5]thiadiazepin-5,5-dioxide-11-yl)-1-propyl)-3-piperidinecarboxylic acid;


30

(R)-1-(3-(5-Methyl-5,6-dihydrodibenz[b,e]azepin-11-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(9H-Tribenzo[a,c,e]cyclohepten-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(9H-Tribenzo[b,d,f]azepine-9-yl)propyl)-3-piperidinecarboxylic acid.

- 5 In another preferred embodiment of the invention in formula Ia
- R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and
- Y is $>\underline{N}-CH_2-$, $>\underline{CH}-CH_2-$ or $>\underline{C}=CH-$ wherein only the underscored atom participates in the ring system; and
- 10 X is $-O-$, $-S-$, $-C(R^7R^8)-$, $-CH_2CH_2-$, $-CH=CH-CH_2-$, $-CH_2-CH=CH-$, $-CH_2-(C=O)-$, $-(C=O)-CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-N(R^8)-(C=O)-$, $-(C=O)-N(R^8)-$, $-O-CH_2-$, $-CH_2-O-$, $-S-CH_2-$, $-CH_2-S-$, $-N(R^8)-$, $-(C=O)-$ or $-(S=O)-$ wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and
- p and q are 0; and
- r is 1, 2 or 3; and
- 15 Z is selected from



wherein u is 0 or 1;

- 20 R^3 is $-(CH_2)_mOH$ or $-(CH_2)_sCOR^4$ wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein R^4 is $-OH$, $-NH_2$, $-NHOH$ or C_{1-6} -alkoxy; and
- R^5 is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and
- R^{10a} is hydrogen or C_{1-6} -alkyl; and
- A is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene; or

a pharmaceutically acceptable salt thereof.

Further preferred compounds of the invention include:

- 5 3-(N-Methyl-N-(3-(10,11-dihydrodibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)amino)propionic acid;
- 4-(N-Methyl-N-(3-(10,11-dihydrodibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)amino)butyric acid;
- 10 3-((3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)amino)propionic acid;
- 2-(N(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-N-methyl-amino)succinic acid;
- 15 2-((3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)amino)benzoic acid;
- 2-(N-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-N-methylamino)nicotinic acid;
- 2-((N-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-N-methylamino)methyl)benzoic acid;
- 20 2-((N-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-N-methylamino)-1-cyclohexanecarboxylic acid;
- 25 2-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propylamino)pyridin-3-ol;
- 3-((3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)amino)benzoic acid;
- 2-((3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)amino)benzoic acid;
- 30 2-(N-(3-(3-Chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)amino)benzoic acid;
- 5-Bromo-2-(N-(3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)amino)benzoic acid.

In another preferred embodiment of the invention in formula Ia

R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy;

- 5 Y is $>\underline{N}$ -CH₂- , $>\underline{CH}$ -CH₂- , $>\underline{C}$ =CH- or $>\underline{CH}$ -O- wherein only the underscored atom participates in the ring system; and


X is ortho-phenylene, -O-, -S-, -C(R^7R^8)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R^8)-(C=O)-, -(C=O)-N(R^8)-, -O-CH₂-, -CH₂-O-, -OCH₂O-, -S-CH₂-, -CH₂-S-, -(CH₂)N(R^8)-, -N(R^8)(CH₂)-, -N(CH₃)SO₂-, -SO₂N(CH₃)-, -

- 10 CH(R^9)CH₂-, -CH₂CH(R^9)-, -(C=O)-, -N(R^8)- or -(S=O)- wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and wherein R^9 is C_{1-6} -alkyl or phenyl; and

p and q are 0; and

r is 1, 2 or 3; and

Z is selected from



15

wherein M₁ and M₂ independently are C or N; and


R³⁵ is hydrogen, C_{1-6} -alkyl, phenyl or benzyl; and

R³³ is hydrogen, halogen, trifluoromethyl, nitro or cyano; and

- 20 R³⁴ is hydrogen, halogen, trifluoromethyl, nitro, cyano, -(CH₂)_wCOR³¹, -(CH₂)_wOH or -(CH₂)_wSO₂R³¹ wherein R³¹ is hydroxy, C_{1-6} -alkoxy or NHR³², wherein R³² is hydrogen or C_{1-6} -alkyl, and w is 0, 1 or 2; or

R³⁴ is selected from

31



or a pharmaceutically acceptable salt thereof.

5 Further preferred compounds of the invention include:

2-(4-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)piperazin-1-yl)-3-pyridinecarboxylic acid;

10 2-(4-(3-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-piperazin-1-yl)-3-pyridinecarboxylic acid;

2-(4-(3-(12H-Dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)piperazin-1-yl)-3-pyridinecarboxylic acid;

15

2-(4-(3-(2-Chloro-12H-dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-piperazin-1-yl)-3-pyridinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-(2-pyridyl)piperazine;

20

2-(4-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-propyl)-1-piperazinyl)-3-pyridine-carboxylic acid;

25 2-(4-(2-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-ethyl)-1-piperazinyl)-3-pyridinecarboxylic acid;

6-(4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-2-pyridinecarboxylic acid;

5 2-(4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-3-pyridinecarboxylic acid;

2-(4-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-5-pyridinecarboxylic acid;

10 2-(4-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-3-pyridinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-(2-nitrophenyl)-piperazine;

15 2-(4-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-1-piperazinyl)-benzonitrile;

20 2-(4-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-1-piperazinyl)-benzoic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-(3-trifluoromethyl-2-pyridyl)piperazine;

25 2-(4-(2-(6,11-Dihydro-dibenzo[b,e]thiepin-11-ylidene)ethyl)piperazin-1-yl)-3-pyridinecarboxylic acid;

2-(4-(3-(6,11-Dihydrodibenzo[b,e]thiepin-11-ylidene)-1-propyl)-1-piperazinyl)-3-pyridinecarboxylic acid;

30 2-(4-(2-(6,11-Dihydrodibenzo[b,e]thiepin-11-yloxy)ethyl)-1-piperazinyl)-3-pyridinecarboxylic acid;

6-(4-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperazin-1-yl)-2-pyridinecarboxylic acid;

2-(4-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-3-pyridinecarboxylic acid;

6-(4-(3-(Dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-piperazin-1-yl)-pyridine-2-carboxylic acid.

10 In another preferred embodiment of the invention in formula Ia

R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and


Y is $>\underline{N}$ -, $>\underline{C}H$ -, $>\underline{N}$ -(C=O)- or $>\underline{C}$ =C(R^8)-, wherein only the underscored atom participates in the ring system and R^8 is hydrogen or C_{1-6} -alkyl; and

15 X is ortho-phenylene, -O-, -S-, -C(R^7R^8)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R^8)-(C=O)-, -(C=O)-N(R^8)-, -O-CH₂-, -CH₂-O-, -OCH₂O-, -CH₂OCH₂-, -S-CH₂-, -CH₂-S-, -(CH₂)N(R^8)-, -N(R^8)(CH₂)-, -N(CH₃)SO₂-, -SO₂N(CH₃)-, -CH(R^9)CH₂-, -CH₂CH(R^9)-, -(C=O)-, -N(R^8)- or -(S=O)- wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and wherein R^9 is C_{1-6} -alkyl or phenyl;

20 and p and q are 0; and

r is 0, 1, 2, 3 or 4; and

Z is



25


wherein b is 0, 1, 2, 3 or 4; and

B is -CH=CR⁴⁹-, -CR⁴⁹=CH-, -C≡C-, -(C=O)-, -(C=CH₂)-, -(CR⁴⁹R⁴⁰)-, -CH(OR⁴¹)-, -

CH(NHR⁴¹)-, phenylene, C₃₋₇-cycloalkylene or the completion of a bond, wherein R⁴⁹ and R⁴⁰ independently are hydrogen, C₁₋₆-unbranched alkyl, C₃₋₆-branched alkyl or C₃₋₇-cycloalkyl and

30 wherein R⁴¹ is hydrogen or C₁₋₆-alkyl; and

U is selected from



wherein g is 0, 1 or 2; and

R^{11u} is hydrogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and

5

R^{12u} is $-(CH_2)_hOH$ or $-(CH_2)_jCOR^{17u}$ wherein h is 0, 1, 2, 3, 4, 5 or 6 and j is 0 or 1 and wherein R^{17u} is -OH, -NHR^{20u} or C₁₋₆-alkoxy wherein R^{20u} is hydrogen or C₁₋₆-alkyl; and


R^{13u} is hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and

R^{14u} is hydrogen or C₁₋₆-alkyl; and

C is C₁₋₆-alkylene, C₂₋₆-alkenylene or C₂₋₆-alkynylene; and

— is optionally a single bond or a double bond; and

R^{18u} is selected from




5 wherein M₁ and M₂ independently are C or N; and

R^{19u} is hydrogen, C₁₋₆-alkyl, phenyl or benzyl; and

R^{15u} is hydrogen, halogen, trifluoromethyl, nitro or cyano; and

R^{16u} is hydrogen, halogen, trifluoromethyl, nitro, cyano, -(CH₂)_kCOR^{17u}, -(CH₂)_kOH or - (CH₂)_kSO₂R^{17u} wherein k is 0, 1 or 2; or

10 R^{16u} is selected from



or a pharmaceutically acceptable salt thereof.

15 Further preferred compounds of the invention include:

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

20 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(2R)-piperidinecarboxylic acid;

1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2Z)-butenyl)-(3R)-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propionyl)-(3R)-piperidine-carboxylic acid;

1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-ethyl)-(3R)-piperidine-carboxylic acid;

1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2E)-butenyl)-(3R)-piperidinecarboxylic acid;

1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-methyl-1-ethyl)-(3R)-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-methyl-3-oxopropyl)-(3R)-piperidinecarboxylic acid;

1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-butynyl)-(3R)-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-hydroxy-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(2-(10,11-Dihydro-dibenzo[b,f]azepin-5-ylmethyl)-1-pentyl)-(3R)-piperidinecarboxylic acid;

1-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

5 1-(3-(3-Trifluoromethyl-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

10 1-(3-(3-Methoxy-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(3-(2-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

15 2-(4-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-1-piperazinyl)-nicotinic acid;

20 1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-cyclopropylmethyl)-(3R)-piperidinecarboxylic acid;

25 1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-cyclopentylmethyl)-(3R)-piperidinecarboxylic acid;

1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-ethyl)-(3R)-piperidinecarboxylic acid;

30 (R)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-3-oxopropyl)-3-piperidinecarboxylic acid;

(R)-1-(4-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-benzyl)-3-piperidinecarboxylic acid;

(R)-1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-butyn-1-yl)-3-piperidinecarboxylic acid

5

(R)-1-((2R)-Methyl-3-(3-methyl-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-methylpropyl)-3-piperidinecarboxylic acid;

10

(R)-1-(2-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-methyl-ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

15

(R)-1-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)methyl)-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-3-pyrrolidinylacetic acid;

20

2-(1-(3-(10,11-Dihydrodibenzo[b,f]azepin-5-yl)-(2R)-methylpropyl)-4-piperazinyl)-nicotinic acid;

25

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)methyl)-1-pentyl)-3-piperidinecarboxylic acid;

2-(4-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-hydroxypropyl)piperazin-1-yl)nicotinic acid;

30

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-methyl-3-oxo-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propionyl)-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propionyl)-4-piperidinecarboxylic acid;

5 (R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-ylcarbonyl)-1-benzyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-ylmethyl)-benzyl)-3-piperidinecarboxylic acid;

10

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-3-oxo-1-propyl)-3-piperidinecarboxylic acid;

15

1-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methylpropyl)-4-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-hydroxy-propyl)-4-piperidinecarboxylic acid;

20

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-hydroxypropyl)-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-propoxypropyl)-4-piperidinecarboxylic acid;

25

(R)-1-(2-(N-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-N-methylamino)ethyl)-3-piperidinecarboxylic acid.


In another preferred embodiment of the invention in formula Ia


30

R¹, R^{1a}, R² and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy or methylthio, -NR⁷R⁸ or -SO₂NR⁷R⁸ wherein R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl; and

Y is >CH-O- or >CH-S(O)_y wherein y is 0, 1 or 2, or -N(R⁸)- wherein R⁸ is hydrogen or C₁₋₆-alkyl; and

- X is completion of an optional bond, ortho-phenylene, -O-, -S-, -C(R⁷R⁸)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R⁸)-(C=O)-, -(C=O)-N(R⁸)-, -O-CH₂-, -CH₂-O-, -OCH₂O-, -CH₂OCH₂-, -S-CH₂-, -CH₂-S-, -(CH₂)N(R⁸)-, -N(R⁸)(CH₂)-, -N(CH₃)SO₂-, -SO₂N(CH₃)-, -CH(R⁹)CH₂-, -CH₂CH(R⁹)-, -(C=O)-, -N(R⁸)- or - (S=O)- wherein R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl; and wherein R⁹ is C₁₋₆-alkyl or phenyl; and
- p and q independently are 0 or 1; and
- r is 1, 2, 3 or 4; and
- Z is selected from





wherein g is 0, 1 or 2; and

R^{11u} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{12u} is $-(CH_2)_hOH$ or $-(CH_2)_jCOR^{17u}$ wherein h is 0, 1, 2, 3, 4, 5 or 6 and j is 0 or 1 and wherein R^{17u} is $-OH$, $-NHR^{20u}$ or C_{1-6} -alkoxy wherein R^{20u} is hydrogen or C_{1-6} -alkyl; and


R^{13u} is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{14u} is hydrogen or C_{1-6} -alkyl; and

C is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene; and

... is optionally a single bond or a double bond; and

R^{18u} is selected from




wherein M_1 and M_2 independently are C or N; and

R^{19u} is hydrogen, C_{1-6} -alkyl, phenyl or benzyl; and

R^{15u} is hydrogen, halogen, trifluoromethyl, nitro or cyano; and

R^{16u} is hydrogen, halogen, trifluoromethyl, nitro, cyano, $-(CH_2)_kCOR^{17u}$, $-(CH_2)_kOH$ or $-(CH_2)_kSO_2R^{17u}$ wherein k is 0, 1 or 2; or

R^{16u} is selected from



or a pharmaceutically acceptable salt thereof.

5 Further preferred compounds of the invention include:

1-(2-(10,11-Dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-(3R)-piperidinecarboxylic acid;

10 1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;

15

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

20

1-(2-(8-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

25

1-(2-(8-Methylthio-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydrodibenzo[b,f]oxepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-ylsulfanyl)ethyl)-3-piperidinecarboxylic acid;

5

(R)-1-(11H-Dibenz[b,f][1,4]oxathiepin-11-ylmethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-7-fluoro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

10

(R)-1-(2-(2,4-Dichloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid.

In another preferred embodiment of the invention in formula Ia

15 R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and




Y is $>\underline{N}$ -CH₂-, $>\underline{CH}$ -CH₂- or $>\underline{C}$ =CH- wherein only the underscored atom participates in the ring system; and

20 X is ortho-phenylene, -O-, -S-, -C(R⁷R⁸)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R⁸)-(C=O)-, -(C=O)-N(R⁸)-, -O-CH₂-, -CH₂-O-, -OCH₂O-, -S-CH₂-, -CH₂-S-, -(CH₂)N(R⁸)-, -N(R⁸)(CH₂)-, -N(CH₃)SO₂-, -SO₂N(CH₃)-, -CH(R⁹)CH₂-, -CH₂CH(R⁹)-, -(C=O)-, -N(R⁸)- or -(S=O)- wherein R⁷ and R⁸ independently are hydrogen or C_{1-6} -alkyl; and wherein R⁹ is C_{1-6} -alkyl or phenyl; and

p and q are 0; and

25 r is 1, 2 or 3; and

Z is selected from



wherein R⁵³ is -(CH₂)_{pp}COOH wherein pp is 2, 3, 4, 5 or 6; or

30 a pharmaceutically acceptable salt thereof.

Further preferred compounds of the invention include:

3-(1-(3-(10,11-Dihydrodibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-3-yl)propionic acid;

5

3-(1-(3-(10,11-Dihydrodibenzo[b,f]azepin-5-yl)-1-propyl)piperidin-3-yl)propionic acid;

3-(1-(2-(10,11-Dihydrodibenzo[a,d]cyclohepten-5-ylidene)ethyl)piperidin-4-yl)propionic acid;

10 3-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)piperidin-4-yl)propionic acid;

15 3-(1-(3-(Thioxanthen-9-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(Xanthen-9-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

20

4-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)-butyric acid;

3-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-2-yl)-

25 propionic acid;

3-(1-(3-(1-Bromo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

30 3-(1-(3-(2-Fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(2-Trifluoromethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-piperidin-4-yl)propionic acid;

3-(1-(3-(2-Hydroxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

5 3-(1-(3-(2-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(2-Methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-piperidin-4-yl)propionic acid;

10 3-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

15 3-(1-(3-(2-Fluoro-6,11-dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-4-yl)-propionic acid;

4-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-4-yl)butyric acid;

20 3-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-3-yl)propionic acid;

3-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-2-yl)propionic acid;

25 3-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)pyrrolidin-3-yl)-propionic acid;

4-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)pyrrolidin-3-yl)-butyric acid;

30 3-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)pyrrolidin-3-yl)propionic acid;

3-(1-(3-(10H-Anthracen-9-ylidene)-1-propyl)pyrrolidin-3-yl)propionic acid;

3-(1-(3-(Dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)pyrrolidin-3-yl)propionic acid;

3-(1-(3-(10H-Anthracen-9-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

5 3-(1-(3-(Dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

5-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)piperidin-4-yl)pentanoic acid;

10 5-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-4-yl)pentanoic acid;

5-(1-(3-(Thioxanthen-9-ylidene)-1-propyl)piperidin-4-yl)pentanoic acid;

5-(1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)piperidin-4-yl)pentanoic acid.

15

In another preferred embodiment of the invention in formula Ia

R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

Y is $>\underline{N}-CH_2-$, $>\underline{CH}-CH_2-$, $>\underline{C}=CH-$ or $>\underline{CH}-O-$ wherein only the underscored atom partici-

20 pates in the ring system; and


X is ortho-phenylene, -O-, -S-, $-C(R^7R^8)-$, $-CH_2CH_2-$, $-CH=CH-CH_2-$, $-CH_2-CH=CH-$, $-CH_2-(C=O)-$, $-(C=O)-CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-N(R^8)-(C=O)-$, $-(C=O)-N(R^8)-$, $-O-CH_2-$, $-CH_2-O-$, $-OCH_2O-$, $-S-CH_2-$, $-CH_2-S-$, $-(CH_2)N(R^8)-$, $-N(R^8)(CH_2)-$, $-N(CH_3)SO_2-$, $-SO_2N(CH_3)-$, $-CH(R^9)CH_2-$, $-CH_2CH(R^9)-$, $-(C=O)-$, $-N(R^8)-$ or $-(S=O)-$ wherein R^7 and R^8 independently are

25 hydrogen or C_{1-6} -alkyl; and wherein R^9 is C_{1-6} -alkyl or phenyl; and

p and q are 0; and

r is 1, 2 or 3; and

Z is



30

wherein tt and t independently are 0, 1 or 2; and

R⁶³ is H, C₁₋₆-alkyl or optionally substituted benzyl;

R⁶⁴ and R⁶⁵ independently are H, C₁₋₈-alkyl, C₃₋₇-cycloalkyl, phenyl, thienyl, benzyl, or R⁶⁴ and

R⁶⁵ together with the C-atom they are attached to form a 3 - 8 membered carbocyclic ring;

and

- 5 R⁶⁶ is H or C₁₋₆-alkyl; or
a pharmaceutically acceptable salt thereof.

Further preferred compounds of the invention include:

- 10 1-(2-(10,11-Dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-(3R)-piperidinecarboxylic acid;

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

15

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;

20

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

25

1-(2-(8-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(8-Methylthio-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

30

(R)-1-(2-(10,11-Dihydrodibenzo[b,f]oxepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-ylsulfanyl)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(11H-Dibenz[b,f][1,4]oxathiepin-11-ylmethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-7-fluoro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-

5 piperidinecarboxylic acid;

(R)-1-(2-(2,4-Dichloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid.

10 In another preferred embodiment of the invention in formula Ia

R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

Y is $>\underline{N}-CH_2-$, $>\underline{C}H-CH_2-$ or $>\underline{C}=CH-$ wherein only the underscored atom participates in the

15 ring system; and






X is ortho-phenylene, -O-, -S-, $-C(R^7R^8)-$, $-CH_2CH_2-$, $-CH=CH-CH_2-$, $-CH_2-CH=CH-$, $-CH_2-(C=O)-$, $-(C=O)-CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-N(R^8)-(C=O)-$, $-(C=O)-N(R^8)-$, $-O-CH_2-$, $-CH_2-O-$, $-OCH_2O-$, $-S-CH_2-$, $-CH_2-S-$, $-(CH_2)N(R^8)-$, $-N(R^8)(CH_2)-$, $-N(CH_3)SO_2-$, $-SO_2N(CH_3)-$, $-CH(R^9)CH_2-$, $-CH_2CH(R^9)-$, $-(C=O)-$, $-N(R^8)-$ or $-(S=O)-$ wherein R^7 and R^8 independently are

20 hydrogen or C_{1-6} -alkyl; and wherein R^9 is C_{1-6} -alkyl or phenyl; and

p and q are 0; and

r is 0, 1 or 2; and

Z is selected from



wherein D is $-\text{CH}_2-$, $-\text{O}-$, $-\text{S}-$ or $-\text{N}(\text{R}^7)-$ wherein R^7 is H or C_{1-6} -alkyl; and R^{3m} is $-(\text{CH}_2)_{mm}\text{OH}$ or $-(\text{CH}_2)_{mp}\text{COR}^4$ wherein mm and mp are 1, 2, 3 or 4 and R^4 is OH, NH_2 , NHOH or C_{1-6} -alkoxy; or a pharmaceutically acceptable salt thereof.

5

Further preferred compounds of the invention include:

3-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-ylmethyl)-pyrrolidin-1-yl)-propionic acid;

10 (2-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-ylmethyl)-morpholin-4-yl)-acetic acid;

(3-(10,11-Dihydro-5H-dibenz[(b,f)azepin-5-ylmethyl)-1-piperidyl)acetic acid.

In another preferred embodiment of the invention in formula Ia

15

R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, cyano, trifluoromethyl, methylthio, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and


Y is $>\text{N}-$, $>\text{CH}-$, $>\text{N}-(\text{C}=\text{O})-$ or $>\text{C}=\text{C}(\text{R}^8)-$, wherein only the underscored atom participates in the ring system and R^8 is hydrogen or C_{1-6} -alkyl; and

20 X is ortho-phenylene, $-\text{O}-$, $-\text{S}-$, $-\text{C}(\text{R}^7\text{R}^8)-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}=\text{CH}-\text{CH}_2-$, $-\text{CH}_2-\text{CH}=\text{CH}-$, $-\text{CH}_2-(\text{C}=\text{O})-$, $-(\text{C}=\text{O})-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}=\text{CH}-$, $-\text{N}(\text{R}^8)-(\text{C}=\text{O})-$, $-(\text{C}=\text{O})-\text{N}(\text{R}^8)-$, $-\text{O}-\text{CH}_2-$, $-\text{CH}_2-\text{O}-$, $-\text{OCH}_2\text{O}-$, $-\text{CH}_2\text{OCH}_2-$, $-\text{S}-\text{CH}_2-$, $-\text{CH}_2-\text{S}-$, $-(\text{CH}_2)\text{N}(\text{R}^8)-$, $-\text{N}(\text{R}^8)(\text{CH}_2)-$, $-\text{N}(\text{CH}_3)\text{SO}_2-$, $-\text{SO}_2\text{N}(\text{CH}_3)-$, $-\text{CH}(\text{R}^9)\text{CH}_2-$, $-\text{CH}_2\text{CH}(\text{R}^9)-$, $-(\text{C}=\text{O})-$, $-\text{N}(\text{R}^8)-$ or $-(\text{S}=\text{O})-$ wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and wherein R^9 is C_{1-6} -alkyl or phenyl; and

25 p and q are 0; and

r is 0, 1, 2, 3 or 4; and

Z is




30 wherein b is 0, 1, 2, 3 or 4; and

B is $-\text{CH}=\text{CR}^{49}-$, $-\text{CR}^{49}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-(\text{C}=\text{O})-$, $-(\text{C}=\text{CH}_2)-$, $-(\text{CR}^{49}\text{R}^{40})-$, $-\text{CH}(\text{OR}^{41})-$, $-\text{CH}(\text{NHR}^{41})-$, phenylene, C_{3-7} -cycloalkylene or the completion of a bond, wherein R^{49} and R^{40}

independently are hydrogen, C_{1-6} -unbranched alkyl, C_{3-6} -branched alkyl or C_{3-7} -cycloalkyl and wherein R^{41} is hydrogen or C_{1-6} -alkyl; and

U is



wherein R⁴² is hydrogen, $-(CH_2)_cOH$ or $-(CH_2)_dCOR^{47}$ wherein c is 0, 1, 2, 3, 4, 5 or 6 and d is
 5 0 or 1 and wherein R⁴⁷ is -OH, -NHR⁴⁴ or C₁₋₆-alkoxy wherein R⁴⁴ is hydrogen or C₁₋₆-alkyl;
 and
 R⁴³ is cyano, -NR⁴⁵R⁴⁶, -NR⁴⁵-V or $-(CHR^{48})_e-V$ wherein R⁴⁵ and R⁴⁶ independently are hydro-
 gen or C₁₋₆-alkyl and wherein e is 0, 1, 2, 3, 4, 5 or 6 and wherein R⁴⁸ is hydrogen, halogen,
 cyano, trifluoromethyl, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy, -NR⁴⁵R⁴⁶ or -COOH, and wherein V is
 10 C₃₋₈-cycloalkyl, aryl or heteroaryl, which rings may optionally be substituted with one or more
 halogen, cyano, trifluoromethyl, hydroxy, methylthio, C₁₋₆-alkyl or C₁₋₆-alkoxy; or
 a pharmaceutically acceptable salt thereof.

Further preferred compounds of the invention include:

15

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-phenyl-4-
 piperidinecarboxylic acid;

20

4-(4-Chlorophenyl)-1-(3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-
 piperidinecarboxylic acid;

4-(4-Methylphenyl)-1-(3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-
 piperidinecarboxylic acid;

25

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-anilino-4-
 piperidinecarboxamide;

2-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidyl)-2-
 phenylacetonitrile;

30

2-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidyl)-2-

phenylacetic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-cyano-4 piperidine-carboxylic acid.

5

In another preferred embodiment of the invention in formula Ib


R^{1b} and R^{2b} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

10 R^{3b} is hydrogen or C_{1-3} -alkyl; and


A_b is C_{1-3} -alkylene; and

Y_b is $>\underline{C}H-CH_2-$, $>\underline{C}=CH-$, $>\underline{C}H-O-$, $>\underline{C}=N-$, $>\underline{N}-CH_2-$ wherein only the underscored atom participates in the ring system; and

Z_b is selected from



15



wherein nb is 1 or 2; and

R^{11b} is hydrogen or C_{1-6} -alkyl; and

- 5 R^{12b} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{13b} is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{14b} is $-(CH_2)_{mb}OH$ or $-(CH_2)_{mb}COR^{15b}$ wherein mb is 0, 1, 2, 3, 4, 5 or 6 and tb is 0 or 1 and

wherein R^{15b} is $-OH$, NH_2 , $-NHOH$ or C_{1-6} -alkoxy; and

- 10 R^{16b} is C_{1-6} -alkyl or $-B_b-COR^{15b}$, wherein B_b is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene and R^{15b} is the same as above; and

... is optionally a single bond or a double bond; or

a pharmaceutically acceptable salt thereof.

- 15 Further preferred compounds of the invention include:

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

20

(R)-1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid ethyl ester;

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

(R)-1-(3-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

5 1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-pyrrolidineacetic acid;

1-(3-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-pyrrolidineacetic acid;

10 (R)-1-(2-(12H-Dibenzo[d,g][1,3]dioxocin-12-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

15 (R)-1-(3-(2-Chloro-12H-dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(12H-Dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-4-piperidinecarboxylic acid;

20 2-Chloro-12-(3-dimethylamino)propylidene-12H-dibenzo[d,g][1,3]dioxocine;

2,10-Dichloro-12-(2-dimethylamino)ethoxy-12H-dibenzo[d,g][1,3]dioxocine;

2,10-Dichloro-12-(3-dimethylamino)propyl-12H-dibenzo[d,g][1,3]dioxocine;

25

2,10-Dichloro-12-(3-dimethylamino-1-methyl)ethoxy-12H-dibenzo[d,g][1,3]dioxocine;

3-Chloro-12-(2-dimethylaminopropylidene)-12H-dibenzo[d,g][1,3]dioxocine;

30 3-Chloro-12-(3-dimethylamino)propylidene-12H-dibenzo[d,g][1,3]dioxocine;

3-Chloro-12-(3-dimethylamino-1-methylpropylidene)-12H-dibenzo[d,g][1,3]dioxocine;

2-Fluoro-12-(3-dimethylamino)propylidene-12H-dibenzo[d,g][1,3]dioxocine;

2-Methyl-12-(3-(4-methyl-1-piperazinyl)propylidene)-12H-dibenzo[d,g][1,3]dioxocine;

2-Chloro-12-(3-(4-methyl-1-piperazinyl)propylidene)-12H-dibenzo[d,g][1,3]dioxocine;

3-Chloro-12-(3-(4-methyl-1-piperazinyl)propylidene)-12H-dibenzo[d,g][1,3]dioxocine;

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)propyl)-3-piperidinecarboxylic acid ethyl ester;

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)propyl)-3-piperidinecarboxylic acid.

In another preferred embodiment of the invention in formula Ic


R^{1c} and R^{2c} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

X_c is ortho-phenylene, -O-, -S-, $-C(R^{6c}R^{7c})-$, $-CH_2CH_2-$, $-CH=CH-CH_2-$, $-CH_2-CH=CH-$, $-CH_2-(C=O)-$, $-(C=O)-CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-N(R^{8c})-(C=O)-$, $-(C=O)-N(R^{8c})-$, $-O-CH_2-$, $-CH_2-O-$, $-OCH_2O-$, $-S-CH_2-$, $-CH_2-S-$, $-(CH_2)N(R^{8c})-$, $-N(R^{8c})(CH_2)-$, $-N(CH_3)SO_2-$, $-SO_2N(CH_3)-$, $-CH(R^{10c})CH_2-$, $-CH_2CH(R^{10c})-$, $-(C=O)-$, $-N(R^{9c})-$ or $-(S=O)-$ wherein R^{6c} , R^{7c} , R^{8c} and R^{9c} independently are hydrogen or C_{1-6} -alkyl, and wherein R^{10c} is C_{1-6} -alkyl or phenyl; and

Y_c is C or N; and

_____ is optionally a single bond or a double bond, and _____ is a single bond when Y_c is N; and m_c is 1, 2, 3, 4, 5 or 6; and

Z_c is $-COOR^{3c}$ or



wherein R^{3c} is H or C_{1-6} -alkyl; or

a pharmaceutically acceptable salt thereof.

Further preferred compounds of the invention include:

1-(2-(10,11-Dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-(3R)-piperidinecarboxylic acid;

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidine-
5 carboxylic acid;

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidine-
carboxylic acid;

10 1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidine-
carboxylic acid;

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidine-
carboxylic acid;

15 1-(2-(8-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidine-
carboxylic acid;

1-(2-(8-Methylthio-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidine-
20 carboxylic acid;

(R)-1-(2-(10,11-Dihydrodibenzo[b,f]oxepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-ylsulfanyl)ethyl)-3-
25 piperidinecarboxylic acid;

(R)-1-(11H-Dibenz[b,f][1,4]oxathiepin-11-ylmethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-7-fluoro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-
30 piperidinecarboxylic acid;

(R)-1-(2-(2,4-Dichloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic
acid.


In another preferred embodiment of the invention in formula Id

R^{1d} and R^{2d} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

5 X_d is -O-, -S- or -S(=O)-; and

m_d is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and

Z_d is selected from



10 wherein R^{3d} is $-(CH_2)_{m_d}OH$ or $-(CH_2)_{p_d}COR^{4d}$ wherein m_d and p_d independently are 0, 1, 2, 3 or 4 and R^{4d} is OH, NH_2 , $NHOH$ or C_{1-6} -alkoxy; or a pharmaceutically acceptable salt thereof.

Further preferred compounds of the invention include:

15

4-(1,3,4,14b-Tetrahydro-2H-dibenzo[b,f]pyrazino[1,2-d][1,4]oxazepin-2-yl)-butanoic acid;

4-(1,3,4,14b-Tetrahydro-2H-dibenzo[b,f]pyrazino[1,2-d][1,4]thiazepin-2-yl)-butanoic acid.

20 The compounds of general formulas Ia-Id may be prepared by using the methods taught in WO9631497, WO9631498, WO9631499, WO9631481, WO9711071, WO9815548, WO9815546, WO9815550, PCT/DK98/00273, PCT/DK98/00271, DK 0367/98, DK 0366/98, DK 1472/97 and DK 1523/98, which are hereby incorporated by reference.

25 It has been demonstrated that the compounds of the present the invention can be used in the treatment of conditions related to angiogenesis according to the following experiment.

PHARMACOLOGICAL METHODS

The effects of compounds of formulas Ia-IId on angiogenesis are suggested by the following experiments. Air pouches were formed on the dorsum of female To mice and were inflamed one day later by injection of 0.5 ml Freund's complete adjuvant supplemented with 0.1% croton oil. Animals were dosed with compounds of formulas Ia-IId given via the drinking water equivalent to 3-30 mg/kg/day. Control animals received normal drinking water. After 6 days the animals received an injection of carmine in gelatine intravenously prior to dissection of the air pouch granuloma. Comparisons of granuloma dry weight, carmine content and vascular index (carmine content/granuloma dry weight) were made between the groups (Colville-Nash et al., J. Pharmacol. Exp. Ther. 274 1463-1472, 1995).

Treatment with compounds of formulas Ia-IId during 6 days gave reductions in the vascular index between 27-36%

Neovascularization in mouse corneas was induced by surgical implantation of a micropellet containing VEGF (vascular endothelial growth factor) or FGF (fibroblast growth factor) 0.6-0.8mm from the corneal limbus. Animals were dosed with compounds of formulas Ia-IId given via the drinking water equivalent to 15 mg/kg/day. After 5 days the stimulation of new blood vessel growth was examined by measuring the vessel length and vessel area (Cao et al., J. Clin. Invest. 98, 2507-2511, 1996).

Treatment with compounds of formulas Ia-IId resulted in a decrease of the vessel area of neovascularization of 30-50%.

PHARMACEUTICAL COMPOSITIONS

The present invention also relates to pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds according to the invention or a pharmaceutically acceptable salt thereof and, usually, such compositions also contain a pharmaceutically acceptable carrier or diluent.

Pharmaceutical compositions comprising a compound of the present invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and

Practise of Pharmacy, 19th Ed., 1995. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.

Typical compositions include a compound according to the invention or a pharmaceutically acceptable acid addition salt thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, syrup, peanut oil, olive oil, gelatine, lactose, terra alba, sucrose, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents. The formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.

The pharmaceutical compositions can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compounds.

The route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral, nasal, pulmonary, transdermal or parenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, topical, intranasal, ophthalmic solution or an ointment, the oral route being preferred.

If a solid carrier is used for oral administration, the preparation may be tableted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.

For nasal administration, the preparation may contain a compound according to the invention dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application. The carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.

For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.

Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.

A typical tablet which may be prepared by conventional tableting techniques may contain:

Core:

25	Active compound (as free compound or salt thereof)	100 mg
	Colloidal silicon dioxide (Aerosil)	1.5 mg
	Cellulose, microcryst. (Avicel)	70 g
	Modified cellulose gum (Ac-Di-Sol)	7.5 mg
	Magnesium stearate	

30

Coating:

HPMC approx.	9 mg
*Mywacett 9-40 T approx.	0.9 mg

*Acylated monoglyceride used as plasticizer for film coating.

The compounds of the invention may be administered to a mammal, especially a human in need of such treatment, prevention, elimination, alleviation or amelioration of indications
5 related to angiogenesis. Such mammals include also animals, both domestic animals, e.g. household pets, and non-domestic animals such as wildlife.

The compounds of the invention may be administered in the form of an alkali metal or earth
alkali metal salt thereof, concurrently, simultaneously, or together with a pharmaceutically
10 acceptable carrier or diluent, especially and preferably in the form of a pharmaceutical composition thereof, in an effective amount.

The compounds of the invention are effective over a wide dosage range. For example, in the treatment of humans, dosages from about 0.1 to about 1000 mg, preferably from about 0.5
15 to about 500 mg of compounds of formula I, conveniently given from 1 to 5 times daily. A most preferable dosage is from about 50 to about 200 mg per dose when administered to e.g. a human. The exact dosage will depend upon the mode of administration, on the therapy desired, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in
20 charge.

Generally, the compounds of the present invention are dispensed in unit dosage form comprising from about 50 to about 200 mg of active ingredient in or together with a pharmaceutically acceptable carrier per unit dosage.


Usually, dosage forms suitable for oral, nasal, pulmonal or transdermal administration comprise from about 0.1 mg to about 1000 mg, preferably from about 0.5 mg to about 500 mg of the compounds according to the invention admixed with a pharmaceutically acceptable carrier or diluent.

The method of treating may be described as the treatment, prevention, elimination, alleviation or amelioration of a condition related to angiogenesis in a subject in need thereof, which comprises the step of administering to the said subject an effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.

Any novel feature or combination of features described herein is considered essential to this invention.

CLAIMS

1. The use of a compound having the general formula Ia



wherein R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, C_{1-6} -alkyl, C_{1-6} -alkoxy, hydroxy, NR^7R^8 , cyano, methylthio or $-SO_2NR^7R^8$ wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and

Y is $>\underline{N}-CH_2-$, $>\underline{CH}-CH_2-$ or $>\underline{C}=CH-$ wherein only the underscored atom participates in the ring system; or

Y is $-\underline{CH}_2N(-)CH_2-$, $-CH_2N(-)\underline{CH}_2-$, $-(\underline{C}=O)N(-)CH_2-$, $-CH_2N(-)(\underline{C}=O)-$, $-\underline{CH}_2CH(-)CH_2-$, $-CH_2CH(-)\underline{CH}_2-$, $-\underline{CH}_2\underline{C}(-)=CH-$, $-CH=\underline{C}(-)\underline{CH}_2-$, $-\underline{OCH}(-)CH_2-$, $-CH_2CH(-)\underline{O}-$, $-\underline{SCH}(-)CH_2-$, $-CH_2CH(-)\underline{S}-$, wherein only the underscored atom participates in the ring system; or

Y is $>\underline{N}-$, $>\underline{CH}-$, $>\underline{N}-(C=O)-$ or $>\underline{C}=C(R^8)-$, wherein only the underscored atom participates in the ring system and R^8 is hydrogen or C_{1-6} -alkyl; or


Y is $>\underline{CH}-O-$ or $>\underline{CH}-S(O)-$, wherein y is 0, 1 or 2, or $-N(R^8)-$ wherein R^8 is hydrogen or C_{1-6} -alkyl, and wherein only the underscored atom participates in the ring system; and

X is completion of an optional bond, ortho-phenylene, $-O-$, $-S-$, $-C(R^7R^8)-$, $-CH_2CH_2-$, $-CH=CH-CH_2-$, $-CH_2-CH=CH-$, $-CH_2-(C=O)-$, $-(C=O)-CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-N(R^8)-(C=O)-$, $-(C=O)-N(R^8)-$, $-O-CH_2-$, $-CH_2-O-$, $-OCH_2O-$, $-CH_2OCH_2-$, $-S-CH_2-$, $-CH_2-S-$, $-(CH_2)N(R^8)-$, $-N(R^8)(CH_2)-$, $-N(CH_3)SO_2-$, $-SO_2N(CH_3)-$, $-CH(R^9)CH_2-$, $-CH_2CH(R^9)-$, $-(C=O)-$, $-N(R^8)-$ or $-(S=O)-$ wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and wherein R^9 is C_{1-6} -alkyl or phenyl; and

p and q independently are 0 or 1; and

r is 0, 1, 2, 3 or 4; and

Z is selected from




5

wherein R^6 is OH or C_{1-6} -alkoxy; and

— is optionally a single bond or a double bond; or

Z is selected from



10

wherein n is 1 or 2;

R^3 is $-(CH_2)_mOH$ or $-(CH_2)_sCOR^4$ wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein R^4 is -OH, -NH₂, -NHOH or C_{1-6} -alkoxy; and

15 R^5 is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and


R^{10} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{11} is hydrogen or C_{1-6} -alkyl; and

... is optionally a single bond or a double bond; or

Z is selected from

5



wherein u is 0 or 1;

R^3 is $-(CH_2)_mOH$ or $-(CH_2)_sCOR^4$ wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein

10 R^4 is $-OH$, $-NH_2$, $-NHOH$ or C_{1-6} -alkoxy; and


R^5 is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{10a} is hydrogen or C_{1-6} -alkyl; and

A is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene; or

15 Z is selected from

65




wherein M_1 and M_2 independently are C or N; and

R^{35} is hydrogen, C_{1-6} -alkyl, phenyl or benzyl; and

5 R^{33} is hydrogen, halogen, trifluoromethyl, nitro or cyano; and

R^{34} is hydrogen, halogen, trifluoromethyl, nitro, cyano, $-(CH_2)_wCOR^{31}$, $-(CH_2)_wOH$ or $-(CH_2)_wSO_2R^{31}$ wherein R^{31} is hydroxy, C_{1-6} -alkoxy or NHR^{32} , wherein R^{32} is hydrogen or C_{1-6} -alkyl, and w is 0, 1 or 2; or


R^{34} is selected from



10

; or

Z is




15

wherein b is 0, 1, 2, 3 or 4; and

B is $-\text{CH}=\text{CR}^{49}-$, $-\text{CR}^{49}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-(\text{C}=\text{O})-$, $-(\text{C}=\text{CH}_2)-$, $-(\text{CR}^{49}\text{R}^{40})-$, $-\text{CH}(\text{OR}^{41})-$, $-\text{CH}(\text{NHR}^{41})-$, phenylene, C_{3-7} -cycloalkylene or the completion of a bond, wherein R^{49} and R^{40} independently are hydrogen, C_{1-6} -unbranched alkyl, C_{3-6} -branched alkyl or C_{3-7} -cycloalkyl and wherein R^{41} is hydrogen or C_{1-6} -alkyl; and


5 U is




wherein R^{42} is hydrogen, $-(\text{CH}_2)_c\text{OH}$ or $-(\text{CH}_2)_d\text{COR}^{47}$ wherein c is 0, 1, 2, 3, 4, 5 or 6 and d is 0 or 1 and wherein R^{47} is $-\text{OH}$, $-\text{NHR}^{44}$ or C_{1-6} -alkoxy wherein R^{44} is hydrogen or C_{1-6} -alkyl; and

10 R^{43} is cyano, $-\text{NR}^{45}\text{R}^{47}$, $-\text{NR}^{45}-\text{V}$ or $-(\text{CHR}^{48})_e-\text{V}$ wherein R^{45} and R^{47} independently are hydrogen or C_{1-6} -alkyl and wherein e is 0, 1, 2, 3, 4, 5 or 6 and wherein R^{48} is hydrogen, halogen, cyano, trifluoromethyl, hydroxy, C_{1-6} -alkyl, C_{1-6} -alkoxy, $-\text{NR}^{45}\text{R}^{47}$ or $-\text{COOH}$, and wherein V is C_{3-8} -cycloalkyl, aryl or heteroaryl, which rings may optionally be substituted with one or more halogen, cyano, trifluoromethyl, hydroxy, methylthio, C_{1-6} -alkyl or C_{1-6} -alkoxy; or

15 U is selected from





wherein g is 0, 1 or 2; and

R^{11u} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{12u} is $-(CH_2)_hOH$ or $-(CH_2)_jCOR^{17u}$ wherein h is 0, 1, 2, 3, 4, 5 or 6 and j is 0 or 1 and wherein R^{17u} is $-OH$, $-NHR^{20u}$ or C_{1-6} -alkoxy wherein R^{20u} is hydrogen or C_{1-6} -alkyl; and


R^{13u} is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{14u} is hydrogen or C_{1-6} -alkyl; and

C is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene; and

--- is optionally a single bond or a double bond; and

R^{18u} is selected from




wherein M_1 and M_2 independently are C or N; and

R^{19u} is hydrogen, C_{1-6} -alkyl, phenyl or benzyl; and

R^{15u} is hydrogen, halogen, trifluoromethyl, nitro or cyano; and


R^{16u} is hydrogen, halogen, trifluoromethyl, nitro, cyano, $-(CH_2)_kCOR^{17u}$, $-(CH_2)_kOH$ or $-(CH_2)_kSO_2R^{17u}$ wherein k is 0, 1 or 2; or

R^{16u} is selected from




; or

5 Z is selected from



wherein R^{53} is $-(CH_2)_{pp}COOH$ wherein pp is 2, 3, 4, 5 or 6; or

10 Z is



wherein tt and t independently are 0, 1 or 2; and


R^{63} is H, C_{1-6} -alkyl or optionally substituted benzyl;

15 R^{64} and R^{65} independently are H, C_{1-6} -alkyl, C_{3-7} -cycloalkyl, phenyl, thienyl, benzyl, or R^{64} and R^{65} together with the C-atom they are attached to form a 3 - 8 membered carbocyclic ring; and

R^{66} is H or C_{1-6} -alkyl; or

20 Z is selected from


69



wherein D is $-\text{CH}_2-$, $-\text{O}-$, $-\text{S}-$ or $-\text{N}(\text{R}^7)-$ wherein R^7 is hydrogen or C_{1-6} -alkyl; and R^{3m} is $-(\text{CH}_2)_{mm}\text{OH}$ or $-(\text{CH}_2)_{mp}\text{COR}^4$ wherein mm and mp are 1, 2, 3 or 4 and R^4 is OH , NH_2 , NHOH or C_{1-6} -alkoxy; or


5

having the general formula Ib



(Ib)

- 10 wherein R^{1b} and R^{2b} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and R^{3b} is hydrogen or C_{1-3} -alkyl; and A_b is C_{1-3} -alkylene; and Y_b is $>\underline{\text{C}}\text{H}-\text{CH}_2-$, $>\underline{\text{C}}=\text{CH}-$, $>\underline{\text{C}}\text{H}-\text{O}-$, $>\underline{\text{C}}=\text{N}-$, $>\underline{\text{N}}-\text{CH}_2-$ wherein only the underscored atom participates in the ring system; and
- 15 Z_b is selected from




- 5 wherein nb is 1 or 2; and
R^{11b} is hydrogen or C₁₋₆-alkyl; and
R^{12b} is hydrogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or phenyl optionally substituted with halogen, trifluoro-
methyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and
R^{13b} is hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and
10 R^{14b} is -(CH₂)_{mb}OH or -(CH₂)_{tb}COR^{15b} wherein mb is 0, 1, 2, 3, 4, 5 or 6 and tb is 0 or 1 and
wherein R^{15b} is -OH, NH₂, -NHOH or C₁₋₆-alkoxy; and

R^{16b} is C_{1-6} -alkyl or $-B_b-COR^{15b}$, wherein B_b is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene and R^{15b} is the same as above; and

--- is optionally a single bond or a double bond; or

- 5 having the general formula 1c



(1c)

wherein R^{1c} and R^{2c} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy;


X_c is ortho-phenylene, $-O-$, $-S-$, $-C(R^{6c}R^{7c})-$, $-CH_2CH_2-$, $-CH=CH-CH_2-$, $-CH_2-CH=CH-$, $-CH_2-(C=O)-$, $-(C=O)-CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-N(R^{8c})-(C=O)-$, $-(C=O)-N(R^{8c})-$, $-O-CH_2-$, $-CH_2-O-$, $-OCH_2O-$, $-S-CH_2-$, $-CH_2-S-$, $-(CH_2)N(R^{8c})-$, $-N(R^{8c})(CH_2)-$, $-N(CH_3)SO_2-$, $-SO_2N(CH_3)-$, $-CH(R^{10c})CH_2-$, $-CH_2CH(R^{10c})-$, $-(C=O)-$, $-N(R^{9c})-$ or $-(S=O)-$ wherein R^{6c} , R^{7c} , R^{8c} and R^{9c} independently are hydrogen or C_{1-6} -alkyl, and wherein R^{10c} is C_{1-6} -alkyl or phenyl;

Y_c is C or N;

--- is optionally a single bond or a double bond, and --- is a single bond when Y_c is N;


mc is 1, 2, 3, 4, 5 or 6; and

Z_c is $-COOR^{3c}$ or





wherein R^{3c} is H or C_{1-6} -alkyl; or

having the general formula 1d



- 5 wherein R^{1d} and R^{2d} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and
 X_d is -O-, -S- or -S(=O)-; and
 rd is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and
 Z_d is selected from



10

wherein R^{3d} is $-(CH_2)_{md}OH$ or $-(CH_2)_{pd}COR^{4d}$ wherein md and pd independently are 0, 1, 2, 3 or 4 and R^{4d} is OH, NH_2 , $NHOH$ or C_{1-6} -alkoxy; or
 a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment of an indication related to angiogenesis.

15


2. The use according to claim 1 wherein angiogenesis is related to cancer.
3. The use according to claim 1 wherein angiogenesis is related to ocular neovascularization.
- 20 4. The use according to anyone of the claims 1-3 wherein in formula Ia
 R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, C_{1-6} -alkyl or C_{1-6} -alkoxy; and
 Y is $>\underline{N}-CH_2-$, $>\underline{CH}-CH_2-$ or $>\underline{C}=CH-$ wherein only the underscored atom participates in the ring system; and

X is -O-, -S-, -C(R⁷R⁸)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂CH₂CH₂-, -CH=CH-, -N(R⁸)-(C=O)-, -O-CH₂-, -(C=O)- or -(S=O)- wherein R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl; and

p and q are 0, and

5 r is 1, 2 or 3; and

Z is selected from



wherein R⁶ is OH or C₁₋₆-alkoxy; and

_____ is optionally a single bond or a double bond; or

10 a pharmaceutically acceptable salt thereof.

5. The use according to anyone of the claims 1- 4 wherein the compound is selected from the following:

15 (R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(S)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

20

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid;

(R)-1-(3-(Fluoren-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

25

1-(3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(Thioxanthen-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-butyl)-3-piperidinecarboxylic acid;

5 (R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

10 (R)-1-(3-(10H-Phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10H-Phenoxazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(S)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

15

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-pyrrolidinacetic acid;

(R)-1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

20

(R)-1-(3-(2-Trifluoromethyl-10H-phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(5-Oxo-10H-phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

25 (R)-1-(3-(11H-10-Oxa-5-aza-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid;

30

(R)-1-(3-(6,7-Dihydro-5H-dibenzo[b,g]azocin-12-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-Methoxy-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

5 (R)-1-(3-(10-Methyl-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(9(H)-Oxo-10H-acridin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

10 (R)-1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-ethyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(2-(6,11-Dihydrodibenz[b,e]oxepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid hydrochloride;

15 (R)-1-(3-(2-Chloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Bromo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

20 (R)-1-(3-(2-Fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

25 (R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(Z)-(R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

30 (E)-(R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride,

or a pharmaceutically acceptable salt thereof.


5

6. The use according to anyone of the claims 1-3 wherein in formula Ia R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

Y is $\text{—}\underline{\text{C}}\text{H}_2\underline{\text{N}}(\text{—})\text{CH}_2\text{—}$, $\text{—}\text{CH}_2\underline{\text{N}}(\text{—})\underline{\text{C}}\text{H}_2\text{—}$, $\text{—}(\underline{\text{C}}=\text{O})\underline{\text{N}}(\text{—})\text{CH}_2\text{—}$, $\text{—}\text{CH}_2\underline{\text{N}}(\text{—})(\underline{\text{C}}=\text{O})\text{—}$, $\text{—}\underline{\text{C}}\text{H}_2\underline{\text{C}}\text{H}(\text{—})\text{CH}_2\text{—}$, $\text{—}\text{CH}_2\underline{\text{C}}\text{H}(\text{—})\underline{\text{C}}\text{H}_2\text{—}$, $\text{—}\underline{\text{C}}\text{H}_2\underline{\text{C}}(\text{—})=\text{CH—}$, $\text{—}\text{CH}=\underline{\text{C}}(\text{—})\underline{\text{C}}\text{H}_2\text{—}$, $\text{—}\underline{\text{O}}\underline{\text{C}}\text{H}(\text{—})\text{CH}_2\text{—}$, $\text{—}\text{CH}_2\underline{\text{C}}\text{H}(\text{—})\underline{\text{O}}\text{—}$, $\text{—}\underline{\text{S}}\underline{\text{C}}\text{H}(\text{—})\text{CH}_2\text{—}$, $\text{—}\text{CH}_2\underline{\text{C}}\text{H}(\text{—})\underline{\text{S}}\text{—}$, wherein only the underscored atom participates in the ring system; and
 10 X is —O— , —S— , $\text{—C(R}^7\text{R}^8\text{)—}$, $\text{—CH}_2\text{CH}_2\text{—}$, $\text{—CH=CH—CH}_2\text{—}$, $\text{—CH}_2\text{—CH=CH—}$, $\text{—CH}_2\text{—(C=O)—}$, $\text{—(C=O)—CH}_2\text{—}$, $\text{—CH}_2\text{CH}_2\text{CH}_2\text{—}$, —CH=CH— , $\text{—N(R}^8\text{)—(C=O)—}$, $\text{—(C=O)—N(R}^8\text{)—}$, $\text{—O—CH}_2\text{—}$, $\text{—CH}_2\text{—O—}$, $\text{—S—CH}_2\text{—}$, $\text{—CH}_2\text{—S—}$, $\text{—N(R}^8\text{)—}$, —(C=O)— or —(S=O)— wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and
 15 p and q independently are 0 or 1; and

r is 1, 2 or 3; and

Z is selected from



wherein R^6 is OH or C_{1-6} -alkoxy; and

20 — is optionally a single bond or a double bond; or
 a pharmaceutically acceptable salt thereof.

7. The use according to anyone of the claims 1-3 and 6 wherein the compound is selected from the following:

25

(R)-1-(3-(6,11-Dioxo-6,11-dihydro-5H-dibenz[b,e]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(6,11-Dihydro-5H-dibenz[b,e]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

30

(R)-1-(3-(5,11-Dihydro-10H-dibenzo[b,e][1,4]diazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11H-Dibenzo[b,f][1,4]thiazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

5

(R)-1-(3-(11H-Dibenz[b,f][1,4]oxazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11H-Dibenz[b,f][1,4]oxathiepin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

10 (R)-1-(3-(11H-Dibenzo[b,e][1,4]dithiepin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11H-Dibenz[b,e][1,4]oxathiepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

15 (R)-1-(3-(11,12-Dihydro-10H-dibenz[b,g][1,5]oxazocin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11,12-Dihydro-10H-dibenzo[b,g][1,5]thiazocin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

20 1-(3-(11,12-Dihydro-6H-dibenz[b,f]azocin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(11,12-Dihydro-5H-dibenzo[a,e]cycloocten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

25 1-(3-(6-Oxo-11,12-dihydro-5H-dibenz[b,f]azocin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(7,12-Dihydro-6H-dibenzo[a,d]cycloocten-6-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

30 1-(3-(5-Methyl-5,11-dihydro-dibenz[b,f]azepin-10-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(6-Oxo-5,11-dihydro-5H-dibenz[b,e]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11-Oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

5 (R)-1-(3-(6-Oxo-11,12-dihydro-5H-dibenz[b,f]azocin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-dibenz[b,f][1,4]oxazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

10 (R)-1-(3-(5,6,11,12-Tetrahydro-dibenz[b,f]azocin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11-Oxo-6,11-dihydro-5H-dibenz[b,e]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

15 (R)-1-(3-(5-Methyl-dibenz[b,f]azepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(6,7-Dihydro-5H-dibenz[b,g][1,5]oxazocin-6-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11,12-Dihydro-dibenz[a,e]cycloocten-5-yl)-1-propyl)-3-piperidinecarboxylic acid,

20 or a pharmaceutically acceptable salt thereof.

8. The use according to anyone of the claims 1-3 wherein in formula Ia
 R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, NR^7R^8 , hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and


25 Y is $>\underline{N}-CH_2-$, $>\underline{CH}-CH_2-$ or $>\underline{C}=CH-$ wherein only the underscored atom participates in the ring system; and

X is $-O-$, $-S-$, $-C(R^7R^8)-$, $-CH_2CH_2-$, $-CH=CH-CH_2-$, $-CH_2-CH=CH-$, $-CH_2-(C=O)-$, $-(C=O)-CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-N(R^8)-(C=O)-$, $-(C=O)-N(R^8)-$, $-O-CH_2-$, $-CH_2-O-$, $-S-CH_2-$, $-CH_2-S-$, $-N(R^8)-$, $-(C=O)-$ or $-(S=O)-$ wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and

30 p and q are 0; and

r is 1, 2 or 3; and

Z is selected from



wherein n is 1 or 2; and

R³ is $-(CH_2)_mOH$ or $-(CH_2)_sCOR^4$ wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein

R⁴ is -OH, -NH₂, -NHOH or C₁₋₆-alkoxy; and

5 R⁵ is hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and

R¹⁰ is hydrogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and

R¹¹ is hydrogen or C₁₋₆-alkyl; and

..... is optionally a single bond or a double bond; or

10 a pharmaceutically acceptable salt thereof.

9. The use according to anyone of the claims 1-3 and 8 wherein the compound is selected from the following:

15 1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidine-carboxamide;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-piperidinecarboxylic acid;

(1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidiny)methanol;

4-(4-Chlorophenyl)-1-(3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinol;

5 4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-piperazinecarboxylic acid;

(2S,4R)-1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-hydroxy-2-pyrrolidinecarboxylic acid;

10 4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-morpholinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-aziridinecarboxylic acid;

15 2-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-1,2,3,4-tetrahydro-4-isoquinolinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-methyl-[1,4]-diazepane-6-carboxylic acid;

20 2-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid hydroxamide;

25

(4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)piperazin-1-yl)acetic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

30 4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-piperazinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidineacetic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxamide;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-pyrrolidinecarboxylic acid;

(S)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-pyrrolidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-piperidinecarboxylic acid;

1-(3-(10H-Phenoxazin-10-yl)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(3-Chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidineacetic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-methyl-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-quinuclidiniumcarboxylate;

1-(3-(2,8-Dibromo-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(3,7-Dichloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

5 1-(3-(3,7-Dimethyl-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(3-Dimethylamino-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

10 (R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-piperidinecarboxylic acid;

(S)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-piperidinecarboxylic acid;

15

1-(2-(6,11-Dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(6,11-Dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-4-piperidinecarboxylic acid;

20 1-(2-(2-Chloro-6,11-dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(2-Chloro-6,11-dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-4-piperidinecarboxylic acid;

25

(R)-1-(2-(6,11-Dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid;

1-(3-(2-Bromo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-pyrrolidineacetic acid;

30

1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-pyrrolidineacetic acid;

1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

1-(3-(2-Fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

5 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-2-piperidineacetic acid;

1-(3-(Phenothiazin-10-yl)-1-propyl)-4-piperidinecarboxylic acid;

10 (R)-1-(2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-ethyl)-2-piperidinecarboxylic acid;

1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-ethyl)-4-piperidinecarboxylic acid;

15 1-(2-(6,11-Dihydrodibenzo[b,e]oxepin-11-ylidene)-1-ethyl)-4-piperidinecarboxylic acid,

or a pharmaceutically acceptable salt thereof.

10. The use according to anyone of the claims 1-3 wherein in formula Ia

20 R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and


Y is $>\underline{N}-CH_2-$, $>\underline{C}H-CH_2-$ or $>\underline{C}=CH-$ wherein only the underscored atom participates in the ring system; and

X is ortho-phenylene, $-CH_2-(C=O)-$, $-(C=O)-CH_2-$, $-S-CH_2-$, $-CH_2-S-$, $-(CH_2)N(R^8)-$, $-N(R^8)(CH_2)-$,
25 $-N(CH_3)SO_2-$, $-SO_2N(CH_3)-$, $-CH(R^9)CH_2-$ or $-CH_2CH(R^9)-$ wherein R^8 is hydrogen or C_{1-6} -alkyl and R^9 is C_{1-6} -alkyl or phenyl; and

p and q are 0; and

r is 1, 2 or 3; and

Z is selected from



30

wherein R^6 is OH or C_{1-6} -alkoxy; and

... is optionally a single bond or a double bond; or
a pharmaceutically acceptable salt thereof:

11. The use according to anyone of the claims 1-3 and 10 wherein the compound is
5 selected from the following:

1-(3-(9H-Tribenz[b,d,f]azepin-9-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(Tribenzo[a,c,e]cyclohepten-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

10

1-(3-(5-Methyl-5,6-dihydrodibenz[b,e]azepin-11-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(6-Methyl-6H-dibenzo[c,f][1,2]thiazepin-5,5-dioxide-11-ylidene)-1-propyl)-3-
piperidinecarboxylic acid;

15

1-(3-(10-Methyl-10,11-dihydro-5H-dibenzo[b,e]cyclohepten-5-ylidene)-1-propyl)-3-
piperidinecarboxylic acid;

20

1-(3-(10-Phenyl-10,11-dihydro-5H-dibenzo[b,e]cyclohepten-5-ylidene)-1-propyl)-3-
piperidinecarboxylic acid;

1-(3-(6,11-Dihydro-11H-dibenzo[b,e][1,4]thiazepin-11-yl)-1-propyl)-3-piperidinecarboxylic
acid;

25

1-(3-(10-Methyl-10,11-dihydro-dibenzo[b,e][1,4]diazepin-5-yl)-1-propyl)-3-
piperidinecarboxylic acid;

(R)-1-(3-(10-Oxo-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic
acid;

30

(R)-1-(3-(6-Methyl-6,11-dihydro-dibenzo[c,f][1,2,5]thiadiazepin-5,5-dioxide-11-yl)-1-propyl)-3-
piperidinecarboxylic acid;

(R)-1-(3-(5-Methyl-5,6-dihydrodibenz[b,e]azepin-11-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(9H-Tribenzo[a,c,e]cyclohepten-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

5

(R)-1-(3-(9H-Tribenzo[b,d,f]azepine-9-yl)propyl)-3-piperidinecarboxylic acid,

or a pharmaceutically acceptable salt thereof.

10 12. The use according to anyone of the claims 1-3 wherein in formula Ia


R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

Y is $>\underline{N}$ -CH₂-, $>\underline{CH}$ -CH₂- or $>\underline{C}$ =CH- wherein only the underscored atom participates in the ring system; and

15 X is -O-, -S-, -C(R^7R^8)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R^8)-(C=O)-, -(C=O)-N(R^8)-, -O-CH₂-, -CH₂-O-, -S-CH₂-, -CH₂-S-, -N(R^8)-, -(C=O)- or -(S=O)- wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and
p and q are 0; and

r is 1, 2 or 3; and

20 Z is selected from



wherein u is 0 or 1;

R³ is -(CH₂)_mOH or -(CH₂)_sCOR⁴ wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein

R⁴ is -OH, -NH₂, -NHOH or C₁₋₆-alkoxy; and

R⁵ is hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and

R^{10a} is hydrogen or C₁₋₆-alkyl; and

- 5 A is C₁₋₆-alkylene, C₂₋₆-alkenylene or C₂₋₆-alkynylene; or
a pharmaceutically acceptable salt thereof.

13. The use according to anyone of the claims 1-3 and 12 wherein the compound is selected from the following:

10

3-(N-Methyl-N-(3-(10,11-dihydrodibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)amino)propionic acid;

15

4-(N-Methyl-N-(3-(10,11-dihydrodibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)amino)butyric acid;

3-((3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)amino)propionic acid;

20

2-(N(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-N-methyl-amino)succinic acid;

2-((3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)amino)benzoic acid;

2-(N-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-N-methylamino)nicotinic acid;

25

2-((N-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-N-methylamino)methyl)benzoic acid;

2-((N-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-N-methylamino)-1-cyclohexanecarboxylic acid;

30

2-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propylamino)pyridin-3-ol;

3-((3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)amino)benzoic acid;


2-((3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)amino)benzoic acid;

2-(N-(3-(3-Chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)amino)benzoic acid;

- 5 5-Bromo-2-(N-(3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)amino)benzoic acid,

or a pharmaceutically acceptable salt thereof.

- 10 14. The use according to anyone of the claims 1-3 wherein in formula Ia
 R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or
 C_{1-6} -alkoxy;
 Y is $>\underline{N}$ -CH₂-, $>\underline{C}$ H-CH₂-, $>\underline{C}$ =CH- or $>\underline{C}$ H-O- wherein only the underscored atom partici-
pates in the ring system; and
- 15 X is ortho-phenylene, -O-, -S-, -C(R^7R^8)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-
(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R^8)-(C=O)-, -(C=O)-N(R^8)-, -O-CH₂-, -CH₂-
O-, -OCH₂O-, -S-CH₂-, -CH₂-S-, -(CH₂)N(R^8)-, -N(R^8)(CH₂)-, -N(CH₃)SO₂-, -SO₂N(CH₃)-, -
CH(R^9)CH₂-, -CH₂CH(R^9)-, -(C=O)-, -N(R^8)- or -(S=O)- wherein R^7 and R^8 independently are
hydrogen or C_{1-6} -alkyl; and wherein R^9 is C_{1-6} -alkyl or phenyl; and
- 20 p and q are 0; and
 r is 1, 2 or 3; and
 Z is selected from



wherein M_1 and M_2 independently are C or N; and


R^{35} is hydrogen, C_{1-6} -alkyl, phenyl or benzyl; and

R^{33} is hydrogen, halogen, trifluoromethyl, nitro or cyano; and

R^{34} is hydrogen, halogen, trifluoromethyl, nitro, cyano, $-(CH_2)_wCOR^{31}$, $-(CH_2)_wOH$ or -

5 $(CH_2)_wSO_2R^{31}$ wherein R^{31} is hydroxy, C_{1-6} -alkoxy or NHR^{32} , wherein R^{32} is hydrogen or C_{1-6} -alkyl, and w is 0, 1 or 2; or

R^{34} is selected from



10 or a pharmaceutically acceptable salt thereof.

15. The use according to anyone of the claims 1-3 and 14 wherein the compound is selected from the following:

15 2-(4-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)piperazin-1-yl)-3-pyridinecarboxylic acid;

2-(4-(3-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-piperazin-1-yl)-3-pyridinecarboxylic acid;

20

2-(4-(3-(12H-Dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)piperazin-1-yl)-3-pyridinecarboxylic acid;

2-(4-(3-(2-Chloro-12H-dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-piperazin-1-yl)-3-pyridinecarboxylic acid;

25

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-(2-pyridyl)piperazine;

2-(4-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-propyl)-1-piperazinyl)-3-pyridine-carboxylic acid;

5 2-(4-(2-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-ethyl)-1-piperazinyl)-3-pyridinecarboxylic acid;

6-(4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-2-pyridinecarboxylic acid;

10

2-(4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-3-pyridinecarboxylic acid;

15

2-(4-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-5-pyridinecarboxylic acid;

2-(4-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-3-pyridinecarboxylic acid;

20

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-(2-nitrophenyl)-piperazine;

2-(4-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-1-piperazinyl)-benzonitrile;

25

2-(4-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-1-piperazinyl)-benzoic acid;

30

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-(3-trifluoromethyl-2-pyridyl)piperazine;

2-(4-(2-(6,11-Dihydro-dibenzo[b,e]thiepin-11-ylidene)ethyl)piperazin-1-yl)-3-pyridinecarboxylic acid;

2-(4-(3-(6,11-Dihydrodibenzo[b,e]thiepin-11-ylidene)-1-propyl)-1-piperazinyl)-3-pyridinecarboxylic acid;

2-(4-(2-(6,11-Dihydrodibenzo[b,e]thiepin-11-yloxy)ethyl)-1-piperazinyl)-3-pyridinecarboxylic acid;

6-(4-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperazin-1-yl)-2-pyridinecarboxylic acid;

2-(4-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-3-pyridinecarboxylic acid;

6-(4-(3-(Dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-piperazin-1-yl)-pyridine-2-carboxylic acid,

or a pharmaceutically acceptable salt thereof.

16. The use according to anyone of the claims 1-3 wherein in formula Ia R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or

C_{1-6} -alkoxy; and

Y is $>\underline{N}$ -, $>\underline{C}H$ -, $>\underline{N}-(C=O)$ - or $>\underline{C}=C(R^8)$ -, wherein only the underscored atom participates in the ring system and R^8 is hydrogen or C_{1-6} -alkyl; and


X is ortho-phenylene, -O-, -S-, -C(R^7R^8)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R^8)-(C=O)-, -(C=O)-N(R^8)-, -O-CH₂-, -CH₂-

O-, -OCH₂O-, -CH₂OCH₂-, -S-CH₂-, -CH₂-S-, -(CH₂)N(R^8)-, -N(R^8)(CH₂)-, -N(CH₃)SO₂-, -SO₂N(CH₃)-, -CH(R^9)CH₂-, -CH₂CH(R^9)-, -(C=O)-, -N(R^8)- or -(S=O)- wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and wherein R^9 is C_{1-6} -alkyl or phenyl;

and p and q are 0; and

r is 0, 1, 2, 3 or 4; and


Z is



wherein b is 0, 1, 2, 3 or 4; and

B is $-\text{CH}=\text{CR}^{49}-$, $-\text{CR}^{49}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-(\text{C}=\text{O})-$, $-(\text{C}=\text{CH}_2)-$, $-(\text{CR}^{49}\text{R}^{40})-$, $-\text{CH}(\text{OR}^{41})-$, $-\text{CH}(\text{NHR}^{41})-$, phenylene, C_{3-7} -cycloalkylene or the completion of a bond, wherein R^{49} and R^{40} independently are hydrogen, C_{1-6} -unbranched alkyl, C_{3-6} -branched alkyl or C_{3-7} -cycloalkyl and wherein R^{41} is hydrogen or C_{1-6} -alkyl; and

5 U is selected from



wherein g is 0, 1 or 2; and


R^{11u} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{12u} is $-(CH_2)_hOH$ or $-(CH_2)_jCOR^{17u}$ wherein h is 0, 1, 2, 3, 4, 5 or 6 and j is 0 or 1 and wherein R^{17u} is $-OH$, $-NHR^{20u}$ or C_{1-6} -alkoxy wherein R^{20u} is hydrogen or C_{1-6} -alkyl; and R^{13u} is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and R^{14u} is hydrogen or C_{1-6} -alkyl; and

5 C is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene; and

... is optionally a single bond or a double bond; and

R^{18u} is selected from



wherein M_1 and M_2 independently are C or N; and


10 R^{19u} is hydrogen, C_{1-6} -alkyl, phenyl or benzyl; and

R^{15u} is hydrogen, halogen, trifluoromethyl, nitro or cyano; and

R^{16u} is hydrogen, halogen, trifluoromethyl, nitro, cyano, $-(CH_2)_kCOR^{17u}$, $-(CH_2)_kOH$ or $-(CH_2)_kSO_2R^{17u}$ wherein k is 0, 1 or 2; or

R^{16u} is selected from

15



or a pharmaceutically acceptable salt thereof.

17. The use according to anyone of the claims 1-3 and 16 wherein the compound is selected from the following:

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-4-piperidinecarboxylic acid;

- 5 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(2R)-piperidinecarboxylic acid;

1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2Z)-butenyl)-(3R)-piperidinecarboxylic acid;

10

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propionyl)-(3R)-piperidine-carboxylic acid;

- 15 1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-ethyl)-(3R)-piperidine-carboxylic acid;

1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2E)-butenyl)-(3R)-piperidinecarboxylic acid;

- 20 1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-methyl-1-ethyl)-(3R)-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-methyl-3-oxopropyl)-(3R)-piperidinecarboxylic acid;

25

1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-butyryl)-(3R)-piperidinecarboxylic acid;

- 30 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-hydroxy-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(2-(10,11-Dihydro-dibenzo[b,f]azepin-5-ylmethyl)-1-pentyl)-(3R)-piperidinecarboxylic acid;

5 1-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(3-(3-Trifluoromethyl-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

10 1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

1-(3-(3-Methoxy-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

15

1-(3-(2-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

20

2-(4-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-1-piperazinyl)-nicotinic acid;

1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-(3R)-piperidinecarboxylic acid;

25

1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-cyclopropylmethyl)-(3R)-piperidinecarboxylic acid;

1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-cyclopentylmethyl)-(3R)-piperidinecarboxylic acid;

30

1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-ethyl)-(3R)-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-3-oxopropyl)-3-piperidinecarboxylic acid;

(R)-1-(4-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-benzyl)-3-piperidinecarboxylic acid;

(R)-1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-butyn-1-yl)-3-piperidinecarboxylic acid

(R)-1-((2R)-Methyl-3-(3-methyl-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-methylpropyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-methyl-ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)methyl)-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-3-pyrrolidinylacetic acid;

2-(1-(3-(10,11-Dihydrodibenzo[b,f]azepin-5-yl)-(2R)-methylpropyl)-4-piperazinyl)-nicotinic acid;

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)methyl)-1-pentyl)-3-piperidinecarboxylic acid;

2-(4-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-hydroxypropyl)piperazin-1-yl)nicotinic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-methyl-3-oxo-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propionyl)-3-piperidinecarboxylic acid;

5

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propionyl)-4-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-ylcarbonyl)-1-benzyl)-3-piperidinecarboxylic acid;

10

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-ylmethyl)-benzyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-3-oxo-1-propyl)-3-piperidinecarboxylic acid;

15

1-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methylpropyl)-4-piperidinecarboxylic acid;

20 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-hydroxy-propyl)-4-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-hydroxypropyl)-3-piperidinecarboxylic acid;

25

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-propoxypropyl)-4-piperidinecarboxylic acid;

(R)-1-(2-(N-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-N-methylamino)ethyl)-3-piperidinecarboxylic acid,

30

or a pharmaceutically acceptable salt thereof.

18. The use according to anyone of the claims 1-3 wherein in formula Ia

R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl, C_{1-6} -alkoxy or methylthio, $-NR^7R^8$ or $-SO_2NR^7R^8$ wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and

Y is $>\underline{CH}-O-$ or $>\underline{CH}-S(O)_y$, wherein y is 0, 1 or 2, or $-N(R^8)-$ wherein R^8 is hydrogen or C_{1-6} -alkyl; and


X is completion of an optional bond, ortho-phenylene, $-O-$, $-S-$, $-C(R^7R^8)-$, $-CH_2CH_2-$, $-CH=CH-CH_2-$, $-CH_2-CH=CH-$, $-CH_2-(C=O)-$, $-(C=O)-CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-N(R^8)-(C=O)-$, $-(C=O)-N(R^8)-$, $-O-CH_2-$, $-CH_2-O-$, $-OCH_2O-$, $-CH_2OCH_2-$, $-S-CH_2-$, $-CH_2-S-$, $-(CH_2)N(R^8)-$, $-N(R^8)(CH_2)-$, $-N(CH_3)SO_2-$, $-SO_2N(CH_3)-$, $-CH(R^9)CH_2-$, $-CH_2CH(R^9)-$, $-(C=O)-$, $-N(R^8)-$ or $-(S=O)-$ wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and wherein R^9 is C_{1-6} -alkyl


or phenyl; and

p and q independently are 0 or 1; and

r is 1, 2, 3 or 4; and

Z is selected from





wherein g is 0, 1 or 2; and

R^{11u} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{12u} is $-(CH_2)_hOH$ or $-(CH_2)_jCOR^{17u}$ wherein h is 0, 1, 2, 3, 4, 5 or 6 and j is 0 or 1 and wherein R^{17u} is $-OH$, $-NHR^{20u}$ or C_{1-6} -alkoxy wherein R^{20u} is hydrogen or C_{1-6} -alkyl; and


R^{13u} is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{14u} is hydrogen or C_{1-6} -alkyl; and

C is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene; and

— is optionally a single bond or a double bond; and

R^{18u} is selected from




wherein M_1 and M_2 independently are C or N; and

R^{19u} is hydrogen, C_{1-6} -alkyl, phenyl or benzyl; and

R^{15u} is hydrogen, halogen, trifluoromethyl, nitro or cyano; and

R^{16u} is hydrogen, halogen, trifluoromethyl, nitro, cyano, $-(CH_2)_kCOR^{17u}$, $-(CH_2)_kOH$ or $-(CH_2)_kSO_2R^{17u}$ wherein k is 0, 1 or 2; or

R^{16u} is selected from



or a pharmaceutically acceptable salt thereof.

- 5 19. The use according to anyone of the claims 1-3 and 18 wherein the compound is selected from the following:

1-(2-(10,11-Dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-(3R)-piperidinecarboxylic acid;

10

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;

15

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

20

1-(2-(8-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

25

1-(2-(8-Methylthio-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydrodibenzo[b,f]oxepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-ylsulfanyl)ethyl)-3-
5 piperidinecarboxylic acid;

(R)-1-(11H-Dibenz[b,f][1,4]oxathiepin-11-ylmethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-7-fluoro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-
10 piperidinecarboxylic acid;

(R)-1-(2-(2,4-Dichloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic
acid,

15 or a pharmaceutically acceptable salt thereof.

20. The use according to anyone of the claims 1-3 wherein in formula Ia
R¹, R^{1a}, R² and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or
C₁₋₆-alkoxy; and

20 Y is >N-CH₂-, >CH-CH₂- or >C=CH- wherein only the underscored atom participates in the
ring system; and




X is ortho-phenylene, -O-, -S-, -C(R⁷R⁸)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-
(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R⁸)-(C=O)-, -(C=O)-N(R⁸)-, -O-CH₂-, -CH₂-
O-, -OCH₂O-, -S-CH₂-, -CH₂-S-, -(CH₂)N(R⁸)-, -N(R⁸)(CH₂)-, -N(CH₃)SO₂-, -SO₂N(CH₃)-, -

25 CH(R⁹)CH₂-, -CH₂CH(R⁹)-, -(C=O)-, -N(R⁸)- or -(S=O)- wherein R⁷ and R⁸ independently are
hydrogen or C₁₋₆-alkyl; and wherein R⁹ is C₁₋₆-alkyl or phenyl; and

p and q are 0; and

r is 1, 2 or 3; and

Z is selected from



30

wherein R⁵³ is -(CH₂)_{pp}COOH wherein pp is 2, 3, 4, 5 or 6; or

a pharmaceutically acceptable salt thereof.

21. The use according to anyone of the claims 1-3 and 20 wherein the compound is selected from the following:

5

3-(1-(3-(10,11-Dihydrodibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-3-yl)propionic acid;

3-(1-(3-(10,11-Dihydrodibenzo[b,f]azepin-5-yl)-1-propyl)piperidin-3-yl)propionic acid;

10

3-(1-(2-(10,11-Dihydrodibenzo[a,d]cyclohepten-5-ylidene)ethyl)piperidin-4-yl)propionic acid;

3-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

15

3-(1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(Thioxanthen-9-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

20

3-(1-(3-(Xanthen-9-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

25

4-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)-butyric acid;

3-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-2-yl)-propionic acid;

30

3-(1-(3-(1-Bromo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(2-Fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(2-Trifluoromethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-piperidin-4-yl)propionic acid;

5 3-(1-(3-(2-Hydroxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(2-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

10

3-(1-(3-(2-Methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-piperidin-4-yl)propionic acid;

15

3-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

20

3-(1-(3-(2-Fluoro-6,11-dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-4-yl)-propionic acid;

4-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-4-yl)butyric acid;

25

3-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-3-yl)propionic acid;

3-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-2-yl)propionic acid;

30

3-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)pyrrolidin-3-yl)-propionic acid;

4-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)pyrrolidin-3-yl)-butyric acid;

3-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)pyrrolidin-3-yl)propionic acid;

3-(1-(3-(10H-Anthracen-9-ylidene)-1-propyl)pyrrolidin-3-yl)propionic acid;

3-(1-(3-(Dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)pyrrolidin-3-yl)propionic acid;

5

3-(1-(3-(10H-Anthracen-9-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(Dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

10 5-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)piperidin-4-yl)pentanoic acid;

5-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-4-yl)pentanoic acid;

15 5-(1-(3-(Thioxanthen-9-ylidene)-1-propyl)piperidin-4-yl)pentanoic acid;

5-(1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)piperidin-4-yl)pentanoic acid,

or a pharmaceutically acceptable salt thereof.

20

22. The use according to anyone of the claims 1-3 wherein in formula Ia

R¹, R^{1a}, R² and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and

Y is >N-CH₂-, >CH-CH₂-, >C=CH- or >CH-O- wherein only the underscored atom participates in the ring system; and

25

X is ortho-phenylene, -O-, -S-, -C(R⁷R⁸)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R⁸)-(C=O)-, -(C=O)-N(R⁸)-, -O-CH₂-, -CH₂-O-, -OCH₂O-, -S-CH₂-, -CH₂-S-, -(CH₂)N(R⁸)-, -N(R⁸)(CH₂)-, -N(CH₃)SO₂-, -SO₂N(CH₃)-, -CH(R⁹)CH₂-, -CH₂CH(R⁹)-, -(C=O)-, -N(R⁸)- or -(S=O)- wherein R⁷ and R⁸ independently are


30

hydrogen or C₁₋₆-alkyl; and wherein R⁹ is C₁₋₆-alkyl or phenyl; and

p and q are 0; and

r is 1, 2 or 3; and

Z is



wherein t_t and t independently are 0, 1 or 2; and

R^{63} is H, C_{1-6} -alkyl or optionally substituted benzyl;

- 5 R^{64} and R^{65} independently are H, C_{1-6} -alkyl, C_{3-7} -cycloalkyl, phenyl, thienyl, benzyl, or R^{64} and R^{65} together with the C-atom they are attached to form a 3 - 8 membered carbocyclic ring; and

R^{66} is H or C_{1-6} -alkyl; or

a pharmaceutically acceptable salt thereof.

10

23. The use according to anyone of the claims 1-3 and 22 wherein the compound is selected from the following:

15

1-(2-(10,11-Dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-(3R)-piperidinecarboxylic acid;

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

20

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;

25

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

30

1-(2-(8-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(8-Methylthio-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydrodibenzo[b,f]oxepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

5

(R)-1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-ylsulfanyl)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(11H-Dibenz[b,f][1,4]oxathiepin-11-ylmethyl)-3-piperidinecarboxylic acid;

10

(R)-1-(2-(2-Chloro-7-fluoro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2,4-Dichloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid,

15

or a pharmaceutically acceptable salt thereof.

24. The use according to anyone of the claims 1-3 wherein in formula Ia

20 R¹, R^{1a}, R² and R^{2a} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and

Y is $\text{>}\underline{\text{N}}\text{-CH}_2\text{-}$, $\text{>}\underline{\text{C}}\text{H-CH}_2\text{-}$ or $\text{>}\underline{\text{C}}\text{=CH-}$ wherein only the underscored atom participates in the ring system; and


25 X is ortho-phenylene, -O-, -S-, -C(R⁷R⁸)-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R⁸)-(C=O)-, -(C=O)-N(R⁸)-, -O-CH₂-, -CH₂-O-, -OCH₂O-, -S-CH₂-, -CH₂-S-, -(CH₂)N(R⁸)-, -N(R⁸)(CH₂)-, -N(CH₃)SO₂-, -SO₂N(CH₃)-, -CH(R⁹)CH₂-, -CH₂CH(R⁹)-, -(C=O)-, -N(R⁸)- or -(S=O)- wherein R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl; and wherein R⁹ is C₁₋₆-alkyl or phenyl; and

p and q are 0; and

30 r is 0, 1 or 2; and

Z is selected from

106



wherein D is $-\text{CH}_2-$, $-\text{O}-$, $-\text{S}-$ or $-\text{N}(\text{R}^7)-$ wherein R^7 is H or C_{1-6} -alkyl; and R^{3m} is $-(\text{CH}_2)_{mm}\text{OH}$ or $-(\text{CH}_2)_{mp}\text{COR}^4$ wherein mm and mp are 1, 2, 3 or 4 and R^4 is OH, NH_2 , NHOH or C_{1-6} -alkoxy; or

5 a pharmaceutically acceptable salt thereof.

25. The use according to anyone of the claims 1-3 and 24 wherein the compound is selected from the following:

10 3-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-ylmethyl)-pyrrolidin-1-yl)-propionic acid;

(2-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-ylmethyl)-morpholin-4-yl)-acetic acid;

(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-ylmethyl)-1-piperidyl)acetic acid,

15

or a pharmaceutically acceptable salt thereof.

26. The use according to anyone of the claims 1-3 wherein in formula Ia

R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, cyano, trifluoromethyl, methylthio,

20 hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

Y is $>\underline{\text{N}}-$, $>\underline{\text{CH}}-$, $>\underline{\text{N}}-(\text{C}=\text{O})-$ or $>\underline{\text{C}}=\text{C}(\text{R}^8)-$, wherein only the underscored atom participates in the ring system and R^8 is hydrogen or C_{1-6} -alkyl; and

X is ortho-phenylene, $-\text{O}-$, $-\text{S}-$, $-\text{C}(\text{R}^7\text{R}^8)-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}=\text{CH}-\text{CH}_2-$, $-\text{CH}_2-\text{CH}=\text{CH}-$, $-\text{CH}_2-$

$(\text{C}=\text{O})-$, $-(\text{C}=\text{O})-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}=\text{CH}-$, $-\text{N}(\text{R}^8)-(\text{C}=\text{O})-$, $-(\text{C}=\text{O})-\text{N}(\text{R}^8)-$, $-\text{O}-\text{CH}_2-$, $-\text{CH}_2-$


25 $-\text{O}-$, $-\text{OCH}_2\text{O}-$, $-\text{CH}_2\text{OCH}_2-$, $-\text{S}-\text{CH}_2-$, $-\text{CH}_2-\text{S}-$, $-(\text{CH}_2)\text{N}(\text{R}^8)-$, $-\text{N}(\text{R}^8)(\text{CH}_2)-$, $-\text{N}(\text{CH}_3)\text{SO}_2-$, -

SO₂N(CH₃)-, -CH(R⁹)CH₂-, -CH₂CH(R⁹)-, -(C=O)-, -N(R⁸)- or -(S=O)- wherein R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl; and wherein R⁹ is C₁₋₆-alkyl or phenyl; and

p and q are 0; and

r is 0, 1, 2, 3 or 4; and

5 Z is




wherein b is 0, 1, 2, 3 or 4; and

B is -CH=CR⁴⁹-, -CR⁴⁹=CH-, -C≡C-, -(C=O)-, -(C=CH₂)-, -(CR⁴⁹R⁴⁰)-, -CH(OR⁴¹)-, -CH(NHR⁴¹)-, phenylene, C₃₋₇-cycloalkylene or the completion of a bond, wherein R⁴⁹ and R⁴⁰

10 independently are hydrogen, C₁₋₆-unbranched alkyl, C₃₋₆-branched alkyl or C₃₋₇-cycloalkyl and wherein R⁴¹ is hydrogen or C₁₋₆-alkyl; and

U is



wherein R⁴² is hydrogen, -(CH₂)_cOH or -(CH₂)_dCOR⁴⁷ wherein c is 0, 1, 2, 3, 4, 5 or 6 and d is

15 0 or 1 and wherein R⁴⁷ is -OH, -NHR⁴⁴ or C₁₋₆-alkoxy wherein R⁴⁴ is hydrogen or C₁₋₆-alkyl; and

R⁴³ is cyano, -NR⁴⁵R⁴⁶, -NR⁴⁵-V or -(CHR⁴⁸)_e-V wherein R⁴⁵ and R⁴⁶ independently are hydrogen or C₁₋₆-alkyl and wherein e is 0, 1, 2, 3, 4, 5 or 6 and wherein R⁴⁸ is hydrogen, halogen, cyano, trifluoromethyl, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy, -NR⁴⁵R⁴⁶ or -COOH, and wherein V is

20 C₃₋₆-cycloalkyl, aryl or heteroaryl, which rings may optionally be substituted with one or more halogen, cyano, trifluoromethyl, hydroxy, methylthio, C₁₋₆-alkyl or C₁₋₆-alkoxy; or a pharmaceutically acceptable salt thereof.

27. The use according to anyone of the claims 1-3 and 26 wherein the compound is selected from the following:

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-phenyl-4-piperidinecarboxylic acid;

30 4-(4-Chlorophenyl)-1-(3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yliden)-1-propyl)-4-

piperidinecarboxylic acid;

4-(4-Methylphenyl)-1-(3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

5

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-anilino-4-piperidinecarboxamide;

10

2-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidyl)-2-phenylacetonitrile;

2-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidyl)-2-phenylacetic acid;

15

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-cyano-4 piperidine-carboxylic acid,

or a pharmaceutically acceptable salt thereof.

20

28. The use according to anyone of the claims 1-3 wherein in formula Ib R^{1b} and R^{2b} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and


R^{3b} is hydrogen or C_{1-3} -alkyl; and

A_b is C_{1-3} -alkylene; and

25

Y_b is $\text{>}\underline{\text{C}}\text{H-CH}_2\text{-}$, $\text{>}\underline{\text{C}}\text{=CH-}$, $\text{>}\underline{\text{C}}\text{H-O-}$, $\text{>}\underline{\text{C}}\text{=N-}$, $\text{>}\underline{\text{N}}\text{-CH}_2\text{-}$ wherein only the underscored atom participates in the ring system; and

Z_b is selected from



5 wherein nb is 1 or 2; and

R^{11b} is hydrogen or C_{1-6} -alkyl; and

R^{12b} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{13b} is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

10 R^{14b} is $-(CH_2)_{mb}OH$ or $-(CH_2)_{tb}COR^{15b}$ wherein mb is 0, 1, 2, 3, 4, 5 or 6 and tb is 0 or 1 and, wherein R^{15b} is $-OH$, NH_2 , $-NHOH$ or C_{1-6} -alkoxy; and

R^{16b} is C₁₋₆-alkyl or -B_b-COR^{15b}, wherein B_b is C₁₋₆-alkylene, C₂₋₆-alkenylene or C₂₋₆-alkynylene and R^{15b} is the same as above; and

... is optionally a single bond or a double bond; or
a pharmaceutically acceptable salt thereof.

5

29. The use according to anyone of the claims 1-3 and 28 wherein the compound is selected from the following:

10

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid ethyl ester;

15

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

(R)-1-(3-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

20

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-pyrrolidineacetic acid;

1-(3-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-pyrrolidineacetic acid;

25

(R)-1-(2-(12H-Dibenzo[d,g][1,3]dioxocin-12-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

30

(R)-1-(3-(2-Chloro-12H-dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(12H-Dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-4-piperidinecarboxylic acid;

2-Chloro-12-(3-dimethylamino)propylidene-12H-dibenzo[d,g][1,3]dioxocine;

2,10-Dichloro-12-(2-dimethylamino)ethoxy-12H-dibenzo[d,g][1,3]dioxocine;

5

2,10-Dichloro-12-(3-dimethylamino)propyl-12H-dibenzo[d,g][1,3]dioxocine;

2,10-Dichloro-12-(3-dimethylamino-1-methyl)ethoxy-12H-dibenzo[d,g][1,3]dioxocine;

10

3-Chloro-12-(2-dimethylaminopropylidene)-12H-dibenzo[d,g][1,3]dioxocine;

3-Chloro-12-(3-dimethylamino)propylidene-12H-dibenzo[d,g][1,3]dioxocine;

3-Chloro-12-(3-dimethylamino-1-methylpropylidene)-12H-dibenzo[d,g][1,3]dioxocine;

15

2-Fluoro-12-(3-dimethylamino)propylidene-12H-dibenzo[d,g][1,3]dioxocine;

2-Methyl-12-(3-(4-methyl-1-piperazinyl)propylidene)-12H-dibenzo[d,g][1,3]dioxocine;

20

2-Chloro-12-(3-(4-methyl-1-piperazinyl)propylidene)-12H-dibenzo[d,g][1,3]dioxocine;

3-Chloro-12-(3-(4-methyl-1-piperazinyl)propylidene)-12H-dibenzo[d,g][1,3]dioxocine;

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)propyl)-3-piperidinecarboxylic acid ethyl ester;

25

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)propyl)-3-piperidinecarboxylic acid,

or a pharmaceutically acceptable salt thereof.

30

30. The use according to anyone of the claims 1-3 wherein in formula Ic R^{1c} and R^{2c} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and


X_c is ortho-phenylene, -O-, -S-, -C(R^{6c}R^{7c})-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-(C=O)-, -(C=O)-CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -N(R^{8c})-(C=O)-, -(C=O)-N(R^{8c})-, -O-CH₂-, -CH₂-O-, -OCH₂O-, -S-CH₂-, -CH₂-S-, -(CH₂)N(R^{8c})-, -N(R^{8c})(CH₂)-, -N(CH₃)SO₂-, -SO₂N(CH₃)-, -CH(R^{10c})CH₂-, -CH₂CH(R^{10c})-, -(C=O)-, -N(R^{9c})- or -(S=O)- wherein R^{6c}, R^{7c}, R^{8c} and R^{9c} independently are hydrogen or C₁₋₆-alkyl, and wherein R^{10c} is C₁₋₆-alkyl or phenyl; and

Y_c is C or N; and

 is optionally a single bond or a double bond, and is a single bond when Y_c is N; and

mc is 1, 2, 3, 4, 5 or 6; and

Z_c is -COOR^{3c} or



wherein R^{3c} is H or C₁₋₆-alkyl; or
a pharmaceutically acceptable salt thereof.

31. The use according to anyone of the claims 1-3 and 30 wherein the compound is selected from the following:

1-(2-(10,11-Dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-(3R)-piperidinecarboxylic acid;

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(8-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(8-Methylthio-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidine-carboxylic acid;

5 (R)-1-(2-(10,11-Dihydrodibenzo[b,f]oxepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-ylsulfanyl)ethyl)-3-piperidinecarboxylic acid;

10 (R)-1-(11H-Dibenz[b,f][1,4]oxathiepin-11-ylmethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-7-fluoro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

15 (R)-1-(2-(2,4-Dichloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid,



or a pharmaceutically acceptable salt thereof.

20 32. The use according to anyone of the claims 1-3 wherein in formula 1d R^{1d} and R^{2d} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

X_d is -O-, -S- or -S(=O)-; and

rd is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and

25 Z_d is selected from



wherein R^{3d} is $-(CH_2)_{md}OH$ or $-(CH_2)_{pd}COR^{4d}$ wherein md and pd independently are 0, 1, 2, 3 or 4 and R^{4d} is OH, NH_2 , $NHOH$ or C_{1-6} -alkoxy; or a pharmaceutically acceptable salt thereof.

33. The use according to anyone of the claims 1-3 and 32 wherein the compound is selected from the following:

4-(1,3,4,14b-Tetrahydro-2H-dibenzo[b,f]pyrazino[1,2-d][1,4]oxazepin-2-yl)-butanoic acid;

5

4-(1,3,4,14b-Tetrahydro-2H-dibenzo[b,f]pyrazino[1,2-d][1,4]thiazepin-2-yl)-butanoic acid,

or a pharmaceutically acceptable salt thereof.

10 34. The use according to any of the claims 1-33 wherein the pharmaceutical composition is in a form suitable for oral administration.

35. A method of treating an indication related to angiogenesis comprising administering to a subject in need thereof an effective amount of a compound according to any of the
15 claims 1-33.

36. A method according to claim 35 wherein angiogenesis is related to cancer.

37. A method according to claim 35 wherein angiogenesis is related to ocular
20 neovascularization.

38. Any novel feature or combination of features described herein.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 99/00671

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 31/4523, A61K 31/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5817678 A (BYEONG M. KIM ET AL), 6 October 1998 (06.10.98), column 55, lines 56-63 and column 68, lines 40-42 -----	1-34

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

10 May 2000

Date of mailing of the international search report

11 -05- 2000

Name and mailing address of the ISA/
 Swedish Patent Office
 Box 5055, S-102 42 STOCKHOLM
 Facsimile No. +46 8 666 02 86

Authorized officer

Göran Karlsson/EÖ
 Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 99/00671**Box I** Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 35-38
because they relate to subject matter not required to be searched by this Authority, namely:
**A method for treatment of the human or animal body by therapy,
see rule 39.1.**
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a):

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see next sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK99/00671

The subjects, defined by the problems and their means of solution, as listed below are so different from each other that no technical relationship or interaction can be appreciated to be present so as to form a single general inventive concept.

Invention 1. Claim 1, compound (1a) and corresponding parts of claims 2-10 for the manufacture of a pharmaceutical composition for the treatment of an indication related to angiogenesis.

Invention 2. Claim 1, compound (1b) and corresponding parts of claims 2-10 for the manufacture of a pharmaceutical composition for the treatment of an indication related to angiogenesis.

Invention 3. Claim 1, compound (1c) and corresponding parts of claims 2-10 for the manufacture of a pharmaceutical composition for the treatment of an indication related to angiogenesis.

Invention 4. Claim 1, compound (1d) and corresponding parts of claims 2-10 for the manufacture of a pharmaceutical composition for the treatment of an indication related to angiogenesis.

The special technical feature of each invention is the use of each compound (1a), (1b), (1c) or (1d) for the manufacture of a pharmaceutical composition for the treatment of an indication related to angiogenesis. Thus, no significant structural element is shared by all alternative compounds (1a)-(1d).

Information on patent family members

International application No.

PCT/DK 99/00671

Form PCT ISA 210 (patent family annex) (July 1992)